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Abstract 
 
Background 
 
Prolonged recovery after tendon injury has given rise to the need for innovative 
therapy including tendon engineering and cell based therapies. The role of cells in 
grafted or engineered tendon is poorly understood. Clarifying the persistence of 
grafted tissue is fundamentally important to ensure that tissue engineering strategies 
are fit for clinical application. We have devised a murine model for tendon grafting 
that allows for cell tracking and the assessment of tendon integration and 
engineered construct integration. 
 
Materials and methods 
 
We studied the macroscopic and microscopic architecture of the mouse Achilles 
tendon to investigate its properties as a study model. Using microsurgical 
techniques, transgenic tendon grafting procedures were then carried out 
between C57B/L6 wild type and GFP (Green Fluorescent Protein) mice Achilles 
tendon. The temporal and spatial fate of the cells in the graft was assessed using 
quantitative serial histology and immunohistochemistry with Three Dimensional 
reconstruction. Markers for proliferation, collagen synthesis, cell death and 
inflammatory infiltrate were used. The Achilles tendon model was also applied to 
test its applicability to investigate tissue engineered tendon constructs developed 
in vitro. 
 
Results 
 
GFP positive graft cells were seen at Day 3 and Day 21 but disappeared by Day 90. At 
Day 21both graft cells and the cells of the recipient tendon showed intense collagen 
synthetic activity. At the same time both graft and host tendon cells began to show 
14 
 
signs of apoptosis which continued till Day 90. Subcutaneous tissue and paratenon 
maintained a much higher level of cellularity, cell proliferation, collagen synthesis and 
apoptosis at all time. The interplay between cell activity and cell death appear to play 
central role in the integration of the tendon graft. 
 
The persistence of tissue engineered tendon constructs was far less than syngenic 
or autografts. The Achilles tendon model proved to be a robust and economically 
viable model for testing of biomaterials particularly at the early stage of their 
development. 
 
Conclusion 
 
The cells of tendon grafts persist only for a finite time before being repopulated 
by host cells. Tissue engineered cell-based constructs do not provide sufficient 
persistence to substitute in place of syngenic or autologous graft options. Future 
designs of engineered tendon should facilitate tendon integration and aim to 
persist for longer periods of time in order to participate in the healing process.  
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Chapter One 
Literature Review 
16 
 
1.1 Background- Tendon Injury and disease 
 
With increase in the popularity of sporting activities, sport and activity related tendon 
injuries are increasing rapidly (Hess, 2010; Nyyssonen et al., 2008). A survey 
conducted across UK found that around 22 million sports injuries were sustained each 
year   and 42% of these were tendon/ligament injuries (Barclays Space for sport 2005 
survey data http://www.personal.barclays.co.uk). In 2008-2009, 9.3% of   all A&E 
attendances involved tendon injuries (Hospital Episode Statistics- 
http://www.hesonline.nhs.uk) which show the common involvement of these 
structures in accident and injuries. The tendons commonly involved in injuries are the 
tendons of the digits, Achilles tendon of the ankle, the Rotator cuff of the shoulder, 
the tendons in the elbow and wrist. Flexor and extensor tendons of the limbs are 
prone to accidental cuts and lacerations. 
 
Tendons can also be affected by systemic disease like Rheumatoid Arthritis (Ertel, 
1989; Sivakumar et al., 2008), Diabetes Mellitus (Grant et al., 1997) and various 
autoimmune diseases (e.g. SLE, scleroderma) (Furie and Chartash, 1988; Hanly and 
Urowitz, 1986), leading to severe disability.  
 
Tendon injury is also common in athletic animals. 43% of National Hunt horses show 
evidence of tendon disease (Pickersgill et al., 2001) and 14.8% of all horses in flat 
racing in Japan in 1999 suffered injury to the  digital flexor tendons (Takahashi et al., 
2004). 
 
The treatment of tendon injury may involves direct repair (Strickland, 1983) of the 
defect or a more conservative approach of non-operative treatment with or without 
physiotherapy (Seida et al., 2010) may be adapted. The incidence of tendon surgery in 
the NHS is gradually increasing (Figure 1.1). Outcome of tendon surgery is 
unpredictable due to adhesion formation, re-rupture and inadequate functional 
recovery (Taras et al., 1994). During recovery there is   restriction in acts of daily living 
and there is likely to be a   long period of time off work. 
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Figure 1.1- Graphical representation of trend in tendon surgery in the NHS (HES) showing gradual 
increase in primary tendon repair (Blue) and number of tendon harvested (Green) each year between 
1999 and 2005.The number of secondary repair of tendon remain low. Of note is the higher number 
tendon harvest compared to secondary tendon repair indicating the use of tendon graft for other 
clinical indications. 
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When the tendon injury is more severe, leading to loss of a segment of tendon, more 
complex surgery may be required. The defect may occasionally need to be 
reconstructed with a free segment of tendon known as a tendon graft. Often 
tendons can rupture or undergo segmental degeneration. Tendon grafts can be used 
to bridge these defects in tendons or ligaments. Potential sources of tendon grafts 
are autograft (Patient’s own tendon such as the Palmaris Longus in the wrist, 
Plantaris in the leg, Patellar tendon in the knee) (Figure-1.2), allograft (taken from 
another member of the same species, i.e.- cadaveric grafts) and xenograft (harvested 
from a different species such as bovine, porcine etc.). Autograft harvest may leave 
patients with additional scars and residual donor site weakness (Comley and 
Krishnan, 1999; Mastrokalos et al., 2005) while allograft carry risk of disease 
transmission (Kealey, 1997). Both allograft and xenograft carry immunogenic 
implications and can only be transplanted from either an immunocompatible donor 
or after donor graft has received special treatment to render it acellular. 
 
 
Figure 1.2- Tendons that can be used as autografts- (i) Palmaris Longus at the wrist, (ii) Plantaris at the 
back of the leg and (iii) Patellar tendon at the knee joint 
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1.2 Tendon architecture      
 
1.2.1   Microscopic structure 
 
Tendon is a highly organised structure from the molecular level to gross architecture 
(Figure 1.3), a property which allows it to withstand high tensile forces. The 
hierarchical organisation of tendon has been demonstrated at light microscopic, 
ultrastructural and molecular level (Birk and Trelstad, 1986; Oryan and Shoushtari, 
2008; Rowe, 1985).   
                                                                                                               
Figure 1.3 - The organization of tendon structure from collagen molecules to the entire tendon (Towler 
and Gelberman, 2006)- Three polypeptide chains combine together to form a helical tropocollagen 
molecule, five tropocollagens constitute a microfibril, and microfibrils aggregate together to form 
fibrils. Fibrils are then grouped into fibres, fibres into fibre bundles and fibre bundles into fascicles. A 
thin film of loose connective tissue (‘endotenon’) is present between fascicles and/or fibre bundles. 
The endotenon is continuous with a further sheet of connective tissue (epitenon) that surrounds the 
tendon as a whole. 
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The organised architecture of the tendon makes it an ideal structure to investigate 
complex biological events such as grafting and allows for study of cellular trafficking.  
The cells are distributed in parallel rows in between longitudinal fibers and the 
homogeneity allows cellular reorganisation to be studied relatively easily compared 
to heterogeneous structures like skin. 
 
1.2.2 Cells of tendon 
 
The majority of cells of adult tendons display a thin layer of cytoplasm around a large 
heterochromatic nucleus and have been named as “tenocytes” or “tendon 
fibroblasts”. The more active cells, found in immature (Ippolito et al., 1980) or healing 
tendons containing prominent nucleoli, rough endoplasmic reticulum and golgi 
apparatus which produce collagen, have been called “tenoblasts” .  Several studies 
have shown that immature developing tendon is hypercellular and cellularity 
gradually reduces through ageing (Holmes, 1971; Moore and De Beaux, 1987; Oryan 
and Shoushtari, 2008) indicating a relatively quiescent metabolic state of a mature 
tendon in comparison to developing tendon. During healing, tendon cells of a more 
active phenotype are found. 
 
Using cytoplasmic  staining  McNeilly et al.  (McNeilly et al., 1996) demonstrated that 
tenocytes form a three-dimensional network of cells in contact between collagen 
bundles by their long cytoplasmic processes. Immunolabelling for connexin 43 
showed presence of gap junctions on the cytoplasmic processes which suggests that 
they may be involved in load sensing and coordination of response to load. 
  
 A morphological and functional difference between surface cells and internal cells 
described in earlier histological experiment has been re-established through 
immunohistochemical studies. Khan (Khan et al., 1996) described tendon cell 
populations as an outer layer of specialised  fibroblasts and macrophages, (often 
termed epitenon although this term is confusing  as it has different meaning in 
different publications). The tendon core has a different population of fibroblasts. 
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Each cell has a unique response to injury. Banes described tendon cells as synovial 
fibroblast and internal fibroblasts on the basis of sequential enzymatic digestion 
(Banes et al., 1988). More recently a stem cell population has also been identified in 
the tendon, though its role is yet to be characterised. Bi et al.  performed invitro 
studies (Cell culture, RT-PCR, FACS, transplant studies, immunocytochemistry) and 
isolated a cell population from both human and mouse tendons that showed 
increased adherence, could be pushed towards several lineages, expressed both 
tendon specific and stem cell specific markers  and were  named tendon 
stem/progenitor cells (TSPCs) (Bi et al., 2007).This group of cells constituted 6% of the 
cell population in culture and the  authors demonstrated a  similar percentage of slow 
cycling BrdU labeled cells in vivo which they considered homologous to the TSPCs 
identified in culture experiments.  
 
1.2.3 Extracellular Matrix 
 
Tendon matrix is   composed of collagens and proteoglycans (Kjaer 2004). Collagen 
accounts for 65-80% and elastin approximately 1-2% of the dry mass of the tendon 
(Kannus, 2000). Type I collagen is the dominant collagen found in tendon through 
immunofluorescent localization (Williams et al., 1984), electron microscopy (Birk and 
Mayne, 1997), RT-PCR (Heinemeier et al., 2007) and in culture conditions (Gungormus 
and Kolankaya, 2008) but other collagens (e.g. II, III, V, VI, IX, XI) are also present 
(Fukuta et al. 1998; Ottani et al. 2002; Kjaer, 2004). Collagen is responsible for the 
tensile strength of the tendon while proteoglycans provide the viscoelastic 
properties of tendons (Puxkandl et al. 2002; Robinson et al. 2004).Histological, 
immunohistochemical and ultrastructural  studies have shown that injured tendons 
heals by fibrillogenesis (Gigante et al., 1996) and the deposition of new collagen can 
be labelled  by HSP47, a molecular chaperone to procollagen synthesis (Hu et al., 
1995). 
 
Tendons are of two major types based on the presence or absence of their covering 
sheath- intrasynovial and extrasynovial. An intrasynovial tendon has a double layered 
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synovial membrane containing synovial fluid such as the flexor tendons of the hand. 
Tendon sheath fluid assay has shown hyaluronic acid and protein concentrations 
similar to those in normal joint fluid, indicating that flexor tendon sheath fluid has a 
character similar to synovial fluid of joint (Hagberg et al., 1992). This fluid  has been 
shown to be involved in specific functions such as tendon gliding and nutrition of 
tendon tissue (Lundborg et al., 1980). 
 
 An extrasynovial tendon such as the Achilles tendon has no such membrane but is 
covered by a layer of loose connective tissue called paratenon (Graf et al., 1990). The 
two types of tendons have been shown to heal by different mechanism following 
division and also when used as free graft (Gelberman et al., 1992b) and this is 
discussed in more detail in later sections.  
 
1.2.4  Tendon  Vasculature 
 
Blood supply to the tendon has been widely studied using various different 
techniques. Intrasynovial tendons receive nutrition from both synovial fluid bathing 
them as well as from segmental blood vessels (Lundborg et al., 1980). Extrasynovial 
tendons receive blood supply from ossoetendinous and myotendinous  junctions as 
well as blood vessels coming through the mesotenon from the paratenon (Mayer, 
1916). 
 
A substantial number of work has been done on the blood supply of Achilles tendon 
using various different techniques (Reviewed by Fenwick et al., 2002) Injection 
studies in fresh cadavers demonstrated numerous  evenly distributed vessels in the 
paratenon from which vessels ran towards the tendon via the mesotenon  (Carr and 
Norris, 1989). 
 
Cadaveric angiographic testing and light microscopic histological study  showed that 
the blood supply of the Achilles tendon comes from three different areas: the 
musculotendinous and osseotendinous junctions and the paratenon (Ahmed et al., 
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1998) The vessels of the epitenon are chiefly derived proximally from the muscular 
branches and distally from vessels in the region of the heel. The vessels in the 
paratenon are thought to be derived from the main arteries of the leg and that the 
two systems communicate via the mesotenon (Kannus 1997).  
 
Gross anatomy of the mouse leg vasculature follows nomenclature similar to human 
blood vessels. The leg is supplied by two deep vascular bundles-  anterior tibial and 
posterior tibial vessels and the two superficial vascular bundles- sural and saphenous 
vessels (Figure 1.4).The peroneal vessels which contribute to the blood supply of the 
human Achilles tendon in the leg has not been described in the mouse.  
 
 
Figure 1.4 -Blood vessels of the mouse leg showing the posterior tibial vessels lying deep to the 
gastrocnemius muscle while the saphenous and sural vessels lie superficial to the muscle (The 
Anatomy of the Laboratory Mouse, Margaret J. Cook, 1965) 
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1.3 Anatomy of the Achilles tendon  
 
 The Achilles tendon is considered to be the thickest and strongest tendon in the 
human body. The tendon is consistently formed by the tendons of soleus and 
gastrocnemius muscle (Cummins et al., 1946) (Figure 1.5).  The fibres converge as 
they descend but at the same time rotate toward the lateral side. The tendon then 
flattens out before insertion.  
 
The tendon inserts on the posterior surface of the calcaneum bone. The distal tendon 
is protected from the calcaneum during dorsiflexion by the retrocalcaneal bursa 
(Rufai et al., 1995). One of the very few anatomical studies of mice shows that the 
bony anatomy is slightly different from mammalian bony skeleton and the tibia and 
fibula are fused together at the distal end (The Anatomy of the Laboratory Mouse, 
Margaret J. Cook, 1965). The arrangement of the calcaneum and talus appear similar 
to human skeleton (Figure 1.5-1.6). 
 
Using immunohistochemical labelling for type II collagen and routine histology with 
toluidine blue has shown that there are interlocking pieces of calcified fibrocartilage 
and bone at the enthesis region of human Achilles tendon (Milz et al., 2002). 
Fibrocartilage is found in tendon in areas subjected to compression (Benjamin and 
Ralphs, 1998) and this can be visualised with histological  cell morphology, Alcian blue 
stain (Tilman & Schünke 1991) or the presence of type II collagen by 
immunohistochemistry (Peterson et al 1999). 
 
The tendon is covered by a thick layer of paratenon, lying deep to which is a shiny 
vascular membrane, the epitenon (Nisbet, 1960). In between these two layers is a 
thin film of fluid, which gave the tendon a close resemblance to synovial tendons.  
 
In a comparative anatomy study  Holmes demonstrated that 90% of cells in adult dog, 
cat, and monkey Achilles tendon were tenocytes  (Holmes, 1971). The study also 
showed that the percentage of tenocytes increased with weight and age of the rat. 
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In a 50 gm rat 90% of the cells were tenoblasts whereas in a 65 gm rat (older) 71% of 
the cells were tenocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5- Formation of human Achilles tendon by the soleus  and the gastrocnemius muscle in the 
human and inserting into the back of the calcaneum bone; AT- Achilles Tendon 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6--Bony skeleton of mice hind limb and hind foot showing fused tibia and fibula in the leg and 
projecting calcaneum in the foot, where the Achilles tendon inserts (The Anatomy of the Laboratory 
Mouse, Margaret J. Cook, 1965) 
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1.4 Biology of Tendon Healing 
 
In the early twentieth century tendon grafting was considered the recommended 
treatment for all digital tendon injuries (Bunnell's Surgery of the Hand. 5th Edition. 
Philadelphia and Montreal, J. B. Lippincott Company). Over the years tendon grafting 
has become a less popular method for primary tendon repair and today direct repair 
is considered the best treatment for acute  injuries (Strickland, 1983) of flexor and 
extensor tendons. Tendon grafting has remained of interest due to its applicability in 
delayed trauma management or severe injuries (Freilich and Chhabra, 2007; Moore et 
al., 2010) Tendon grafting is also used for reconstruction of ligaments (Victor et al., 
1997) and to replace defective segments of tendon (Maffulli and Leadbetter, 2005).  
 
1.4.1 Current concepts in Tendon healing  
 
Tendon healing follows the general paradigm of healing tissues (Broughton et al., 
2006) and has three chronologically overlapping stages- inflammatory phase, 
proliferative phase (fibroplasia) and remodeling phase (Sharma and Maffulli, 2006; 
Wong et al., 2009).  Classic concepts of tendon healing are of extrinsic healing and 
intrinsic healing. Extrinsic healing denotes healing by cells extrinsic to the tendon, 
such as cells from the sheath, synovium and neighbouring tissues. Fibroblasts are 
thought to arrive to the injury site by vascular adhesions (Gelberman et al., 1984; 
Potenza, 1962). Intrinsic healing is described as healing by cells intrinsic to the 
tendon, more specifically by the tenocytes of the cut ends (Manske and Lesker, 1984; 
Matthews and Richards, 1975). Recent evidence suggest that the process is far more 
complex and cells from inside the tendon and cells from outside the tendon 
contribute to tendon healing (Wong et al., 2009). 
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1.4.2 Cellular activity during tendon healing 
 
During the early period of healing Wu et al.  have shown greater cellularity in both 
epitenon and endotenon areas (Wu et al., 2010). Using immunohistochemical 
techniques on chicken flexor tendon repair model, Wu showed that the total number 
of cells peaked at day 3, while the number of proliferating cells peaked at days 7 and 
21. Apoptotic TUNEL positive cells peaked at day 3 and decreased after day 21 but 
remained greater than baseline levels. Based on Bcl-2 immunostaining the study also 
reported an inhibition of apoptosis between 2-4 weeks. In a patellar longitudinal 
incision model Lui reported that both TUNEL   positive apoptotic cells and   PCNA 
positive proliferative fibroblast like cells peaked at day 28 (Lui et al., 2007; Wu et al., 
2010).  The differences reported in the studies may be due to the differences in the 
types of the wound and types of repair used in each study. 
 
On the basis of immunohistological studies in an intrasynovial mouse flexor tendon 
injury /adhesion model Wong et al (Wong et al., 2009) reported an early inflammatory 
reaction in the subcutaneous tissue surrounding the tendon followed by a peak of 
collagen synthetic activity inside the tendon substance at 21 days. The study showed 
that both the tendon and the surrounding tissue have a dynamic role in intrasynovial 
tendon healing.
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Table 1.1 - Cellular activity in tendon healing as   reported by Wong et al.  (2009) in a 
Murine Flexor Tendon partial injury model 
 
 Tendon Subcutaneous tissue 
CD45(Pan leukocyte 
marker) 
Minimal at early time 
period, peaked at day 14 
and 21 and reduced 
thereafter 
Peaked at 24 hours and 
remained elevated till 
day14 
Ly6G(neutrophil) Minimal expression at all 
times with small peak at 
day3 
Peaked at 24 hours and 
rapidly reduced thereafter 
F480(Macrophage) Marked increase at day 21 Remained high up to day 7 
BrdU(Cell proliferation) High levels between day 
7 to day 28 but activity 
significantly lower than 
surrounding tissue 
Remained high from Day3 
to day21 
Hsp47(Collagen 
synthesis) 
Peaked at day 21 and was 
significantly higher than 
subcutaneous tissue 
Peaked at day 10 
Alpha-SMA (Pericyte and 
myofibroblast) 
No expression in tendon Remained high throughout 
experiment up to day 112 
with peak at day 7  
TUNEL(apoptosis) Gradual increase 
reaching a peak at day 
84, but at a reduced level 
than subcutaneous tissue 
at all times 
Gradual increase reaching 
peak at day 84 
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An emerging concept of tendon healing is the biphasic healing modality where the 
blood and bone marrow derived cells are responsible for the early stages of tendon 
healing and the tendon derived cells contribute to the later stages of healing 
(Kajikawa et al., 2007). Both Kajikawa and Wong report a delayed but active 
involvement of the tendon cells in the healing process, supporting a bimodal healing 
pattern. 
 
In their elegant and innovative study Kajikawa (Kajikawa et al., 2007) investigated the 
spatiotemporal distribution of reparative mesenchymal cells in patellar tendon using 
two types of GFP chimeric rat (Figure 1.7). One of the chimeric rats expressed GFP 
cells only in the patellar tendon and the other one expressed GFP in the bone marrow 
derived cells. In the study a perpendicular wound was made in both types of chimeric   
rat and fibroblast like GFP positive cells were measured in the wounds at various time 
points. 
 
The GFP positive tendon-derived cells were observed in the wounded area from day 3 
and their proliferative activity remained high till day 7. The authors therefore 
concluded that the circulation-derived cells primarily contribute to the healing 
process with the role of the tendon-derived cells increasing with time. A further study 
by the same group (Kajikawa et al., 2008) reported that marrow derived cells did not 
show any collagen synthetic activity (Hsp47) suggesting that these cells do not 
participate in forming neo-tendon. Therefore, despite wide interest in bone marrow 
derived cells in tendon healing their role remains yet undetermined.  The studies 
suggest that cells from the tendon may play the major role in neo-tendon formation. 
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Figure 1.7 - Development of Bone marrow chimeric rat and tendon chimeric rat. Bone marrow chimeric 
rats were developed by irradiating the bone marrow of wild type rat followed by bone marrow 
transplantation from GFP transgenic rat (Left side). These rats therefore expressed GFP in the bone 
marrow derived cells. Tendon chimeric rats were developed by transplanting the patellar tendon from 
GFP rat to the wild type rat (Right side) of the figure. The tendon chimeric rats only expressed GFP in 
their patellar tendon. Both groups of animals received a longitudinal wound to the tendon and the 
studied at 24hours, 3, and 7 days. Modified from Kajikawa et al. (Kajikawa et al., 2007) 
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1.5 Biology of graft healing 
 
The healing of grafts follows a more complex pathway than normal wound healing as 
the grafts need to reestablish their source of nutrition. The biology of graft healing 
has been widely studied for skin graft which is   a common reconstructive surgical 
procedure. Studies of skin graft healing has shown that the graft is initially adhered 
to the recipient site through formation of a fibrin layer and undergoes diffusion of 
nutrients by capillary action from the recipient bed by a process known as plasmatic 
imbibition (Maeda et al., 1999).  The next phase involves the process of inosculation, 
in which there is early anastomosis between donor and recipient vessels (O'Ceallaigh 
et al., 2006). Revascularization of the graft is accomplished through these capillaries 
as well as by neovascularisation which occurs by influx of host cells into the graft in a 
perivascular fashion (O'Ceallaigh et al., 2007).  
 
Remodelling and repopulation of skin grafts is a relatively complex biological process. 
Using antibodies against GFP Matsuo et al (Matsuo et al., 2007) demonstrated that 6 
months after full thickness skin graft transplantation from GFP to wild type mice, GFP 
positive grafted cells survived in the epidermis, hair follicle and sebaceous glands and 
only in part of the dermis, blood vessels, and nerves.  
 
Stem cells of the epidermis localized in the bulge region of the hair follicles have been 
shown to contribute to the formation of   the epidermal structures (Oshima et al 
2001) and authors suggest that graft cell survival is dependent upon the presence of 
stem cells in grafted tissues.  
 
The complex architecture of the skin makes it difficult to separate the role of various 
cells in graft healing. The role of graft derived stem cells in graft survival presents a 
new concept in graft healing and requires further investigation.   
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1.5.1 Biology of Tendon graft healing 
 
The fate of tendon graft has been widely studied in the bone tunnel  where it is 
frequently used for Anterior Cruciate Ligament Reconstruction.  Arnoczky described 
the following stages of tendon autograft healing in the bone tunnel- -avascular 
necrosis, revascularisation, cellular proliferation and remodelling (Arnoczky et al., 
1982).  Amiel & co-workers (Amiel et al., 1986a; Amiel et al., 1986b; Kleiner et al., 
1989) showed that autogenous patellar tendon grafts underwent rapid necrosis and 
repopulation occurred from cells of extra-graft origin. 
 
The mechanism of tendon graft healing outside bone tunnels follows a slightly 
different pathway. Mason and Shearon used canine Extensor Carpi Radialis tendon as 
an autologous end to end graft and performed daily analysis of cellular events from 
day 3 to day 100 (Mason and Shearon, 1932).  The authors grouped their results in 
two overlapping phases. The first phase compromised of events of   the first two 
weeks and the second phase commenced from the second week. In the first phase 
tendon stump and graft is held together by proliferating tissue from the sheath and 
peritendinous area and by the end of this phase the sheath tissue appear to have 
organized into well aligned dense connective tissue.  At this time the sheath has 
many leukocytic cells. In the second phase, the tendon and graft stump starts to 
show mitotic figures (as early as day 4) and cells gradually infiltrates the scar tissue 
situated between the graft and the tendon. The authors reported that on the basis of 
gross and histological criteria the graft remained alive throughout the healing 
process and its appearance was very similar to the rest of the tendon. One of the 
main limitations of the study was the huge number of variables in terms of 
immobilization, suture, use of sheath and the number of animals harvested each day. 
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Table 1.2 -Temporal events in tendon graft healing (Mason and Shearon 
1932) 
 
Days Events 
4-7 days Tendon graft alive 
No sign of cell proliferation (Based on mitotic 
figures) 
Necrosis around silk suture 
8-10  days Graft held together by disorganised tissue of the 
stump and dense relatively more organised tissue of 
the stump  
WBC in sheath still present. Numerous oval shaped 
nuclei in the sheath 
Graft show some proliferative activity 
Areas of necrosis in the centre of the graft 
12-14 days Increased proliferative activity form the stump 
Union of graft and stump appear primarily by 
sheath proliferative activity 
 
3 weeks 
Graft and stump begins to regain uniformity of 
structure 
Reorganisation of cells and collagen fibre bundles 
4-5 weeks Tissue appearance begins to match normal adult 
tendon structure with parallel rows of cells in 
between parallel rows of collagen fibres 
Tendon strength  improved 
100 days Histologically tendon graft inseparable from the 
rest of the tendon 
Stump still slightly wider than the rest of the tendon 
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Later studies (Potenza., 1964; Skoog and Persson., 1954) supported the argument 
that tendon graft remains alive by histological criteria. Potenza used intrasynovial 
flexor tendon grafts to reconstruct the flexor tendons but in order to minimise 
trauma he sutured the graft without displacing it. The graft therefore maintained its 
blood supply inside the flexor sheath area and was in most part undisturbed in its 
anatomical bed, a situation which is unlikely in the clinical setting. Potenza used inert 
stainless steel sutures which was in contrast to earlier grafting studies all of which 
used the highly reactive silk suture(Flynn et al., 1960; Mason and Shearon, 1932) . 
Potenza reported that the tendon cells did not participate in the healing process and 
the reparative cells at the stumps arrived from either the synovial sheath (distal 
stump) or the paratenon (Proximal stump). 
 
Canine studies by Flynn et al (Flynn et al., 1960) also reported early healing by sheath 
tissue followed by healing from stump cells but reported that necrosis occurred in 
whole of the graft and that the transplant was completely replaced by tenoblasts 
from the stump. Use of silk suture, extrasynovial tendon graft and trauma to 
surrounding tissue may be some of the factors involved in Flynn’s contradictory 
evidence. 
 
The healing of tendon graft   has also been shown to be affected by the type of donor 
tendon used as a graft. Canine studies (Seiler et al., 1997) showed that while both 
intrasynovial and extrasynovial tendons remain viable by histological criteria, the 
intrasynovial tendon grafts did not form adhesion. They hypothesized that where an 
intrasynovial tendon graft has been used, healing occurs from the stumps and cells 
migrate into the graft from the apposed ends whereas extrasynovial tendon grafts 
heal by cells invading from all directions through vascular adhesions. Whether the 
cells migrate into the graft or out of the graft is yet to be determined. Table 1.3 
summarises the evidence provided by Gelberman’s group in support of their 
hypothesis (Abrahamsson et al., 1995; Amiel et al., 1995; Ark et al., 1994; Gelberman 
et al., 1992b; Seiler et al., 1993a; Seiler et al., 1997). 
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Table 1.3 - Differences in healing of Extrasynovial and Intrasynovial  
tendon graft 
 
Characteristics Method Intrasynovial Extrasynovial 
Tissue architecture Light microscopy Viable, normal appearing 
surface and internal 
fibroblast at all time points 
Dense circumferential 
adhesion formation 
At 3 weeks degenerative 
changes in the endotenon 
and at 6 weeks 
hypercellular graft 
Collagen 
alignment 
Transmission 
Electron Microscopy 
Well aligned collagen fibres 
through 6 weeks 
Areas of thin, 
disorganised collagen 
fibres with high amplitude 
crimps 
C2ellular survival 
and proliferation 
Intravital 
fluorescent stain 
Ethidium Bromide 
and Calcein and 
confocal microscopy 
Uniform viable surface layer Predominantly nonviable 
fibroblast at   3 weeks 
Increase number of viable 
cells with repopulation 
Neovascularisation  Microangiography Blood vessels visualised at 
proximal and distal repair 
sites 
Blood vessels all around 
the graft-vascular 
adhesions 
Cellular 
productivity 
mRNA for Type I 
procollagen - Insitu 
Hybridisation 
No areas of increase mRNA Areas of increased mRNA 
seen at 2 and 4 weeks in 
the fibroblasts of 
peritendinous adhesion  
DNA synthesis Exvivo 3H thymidine 
uptake and DNA 
content(Biochemical 
method) 
Modest increase Significantly higher than 
intrasynovial tendon 
Mechanical 
strength 
Mechanical testing 
device 
Significantly increased 
angular rotation 
Much lower angular 
rotation 
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Though intrasynovial tendons appear to be better candidates for tendon grafting, 
their low availability as grafts limit their use in the clinical setting and the commonly 
used tendon grafts remain of extrasynovial type (plantaris, palmaris, hamstring, 
patellar tendon etc). 
 
1.5.2 Cellular repopulation in tendon graft 
 
Recent studies on murine flexor tendon   showed that  acellular freeze dried 
allografts were repopulated by 42 days (Hasslund et al., 2008)  (Figure 1.8).  
 
 
Figure 1.8 - Representative histologic sections of the middle segment of the FDL tendon autografts (A–
C) and allografts (D–F) at 14, 28, and 42 days post-surgery. Sections were stained with Orange G/Alcian 
Blue (Scale bar-500µm). Hypercellular fibrotic scar (*) surrounding 14-day and 28-day autografts (A, B) 
that appears to be minimal around the acellular allografts (C, D). By 42 days, the scar tissue appears to 
have significantly remodeled in both autografts (E) and allografts (F). Graft tissue is marked G 
(Hasslund et al., 2008) 
 
Confocal microscopic studies using GFP rat have shown that tendon grafts used for 
both rotator cuff tears (Iwata et al., 2008) and Anterior Cruciate Ligament (Kobayashi 
et al., 2005) reconstruction are replaced by host cells by 28 days. Iwata (Iwata et al., 
2008) reported infiltration of GFP positive host cells into the grafted rotator cuff 
tendon as early as Day 1 day after transplantation and found that host cell invasion 
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occurred from neighbouring synovium, tendon and bone. The study could not 
comment whether the graft acted only as a scaffold or whether viable graft cells are 
required during the remodelling process. Insitu hybridization study of sex 
mismatched animals showed that reseeded cells of acellular tendon grafts persist up 
to 12 weeks and in a small number of animals up to 30 weeks (Thorfinn et al., 2009). 
The mechanism of repopulation and the source of cellular repopulation have not yet 
been established. 
 
1.5.3 Role of other cells in tendon graft 
 
1.5.3.1 Bone marrow derived cells 
 
Apart from tendon and sheath cells other cells may influence graft healing. Much of 
the interest has been centred on the role of marrow derived cells in tendon/graft 
healing. Using GFPBMT mice Zantop showed that bone marrow derived cells 
accumulate in the wound in the early part of graft (both autologous and bioscaffold) 
healing and are predominantly associated with areas of inflammation and 
angiogenesis (Zantop et al., 2006). A reparative role of these cells is yet to be 
established. 
 
1.5.3.2 Inflammatory cells 
 
During  tendon healing in a rat partial tenotomy model,  tendons were seen to be 
filled with a neutrophilic  infiltrate within 6 hours of injury followed by  an influx of 
monocyte and macrophages  within 24 hours (Iwuagwu and McGrouther, 1998).  
Further experiments in the same model showed  that Cd45 positive leukocytes 
comprised of  18 % of the cells at 6 hours of tendon injury  but  reduced to 4% by 72 
hours (Zavahir et al., 2001). In a rat Achilles tendon injury model neutrophil and ED1 
positive systemic macrophages were found to be increased after 24 hours. 
Neutrophils reduced by 70% while the concentration of ED1 positive macrophages 
remained constant at day 3 post-injury (Marsolais et al., 2001).  Neutrophils and ED1 
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positive macrophages returned to control values after 7 and 14 days, respectively. 
ED2 positive macrophages showed a tendency to increase at day 28 suggesting a very 
different role of these macrophages in the healing cascade. Similar results were 
reported for tendon graft healing in the bone tunnel. Immunohistochemical studies 
of rat autografts used for  Anterior Cruciate Ligament reconstruction (Kawamura et 
al., 2005) found that mature tissue macrophages (ED2 positive) show increased 
proliferative activity (PCNA) at day 14 suggesting that a change in phenotype from 
proinflammmatory to pro-regenerative as healing progresses. In  a c57Bl/6 mice 
Achilles tendon injury model  liposomal clodronate induced macrophage depletion 
has also shown a reduction in  the density of proliferative cells (BrdU positive) in 
tendons by 36%  (Godbout et al., 2010). On the other hand a recent study (Hays et al., 
2008) has shown that a reduction in liposomal clodronate induced macrophage 
depletion during rat ACL reconstruction led to better morphologic and biomechanical 
healing at the bone-tendon interface of such repairs. In culture conditions human 
monocytes and macrophages have been reported to express virtually all known 
collagen and collagen-related mRNAs (Schnoor et al., 2008). The macrophages 
secreted a large amount of type VI collagen which is known to be involved in 
modulation of cell-cell and cell-matrix interactions. The authors suggest that the 
production of type VI collagen is a marker for a nondestructive, matrix-conserving 
macrophage phenotype which may be involved in physiological and pathological 
conditions in vivo. It is possible that different macrophage play completely or even 
opposing functions and may therefore be an important player  in tendon healing and 
graft integration than was previously thought and this possibility requires further 
investigation. 
 
1.5.4 Cytokines and growth factors in graft healing 
 
Histology, biomechanical and molecular testing of freeze dried allograft and 
autografts in murine model showed that adhesion reduced after 28 days and this 
peak in remodelling directly corresponded to high GDF-5 (Growth and Differentiation 
Factor- 5) level (Hasslund et al., 2008). The authors also report that live autografts 
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significantly upregulated   VEGFa in 28-day autografts but the TGFβ1 expression levels 
were not increased. A further study by the group (Basile et al., 2008) tested the 
effect of GDF-5 gene delivery to the healing site and found limited efficacy due to the 
short duration of its action. It is likely that the cytokine and growth factor profile 
during tendon graft healing closely resembles that of tendon healing and  the many 
growth factor, cytokines and other exogenous substances  currently under 
investigation to improve tendon healing  (Reviewed by Doure et al.,2008) may also 
be useful in improving tendon graft and construct integration. 
  
1.5.5 Apoptosis in graft healing 
 
Apoptosis has been shown to be a part of the healing process of wounded tendons. 
Lui  (Lui et al., 2007) reported that TUNEL positive cells peaked at 28 days following 
tendon wounding while Wong  (Wong et al., 2009) reported a peak at 84 days in a 
mice tendon adhesion model. A recent study reports a much earlier peak in apoptosis 
in the healing tendons at day 3, followed about 10 days later by the peak proliferation 
period (Wu et al., 2010). Using Bcl-2 immunohistochemistry, Wu also found that 
apoptosis was inhibited between 2 and 4 weeks. Apoptosis may be triggered by loss 
of mechanical integrity and the need for realignment by the neotendon cells. 
Apoptosis has been shown to be induced  both by  mechanical loading of  intact 
tendon (Scott et al., 2005) or by the lack of it (Egerbacher et al., 2008).   In terms of 
healing of transplanted tissue, apoptosis has been shown to contributes to both graft 
rejection and the establishment of graft tolerance  (Zavazava and Kabelitz, 2000). 
The role of apoptosis in tendon graft healing has not been investigated. 
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1.5.6 Vascularisation of tendon grafts 
 
Though tendons have been designated as relatively avascular tissue, 
neovascularisation has been shown to be an integral part of both tendon and tendon 
graft healing. Earlier work by Peacock showed a profuse vascular network during 
healing and maturation of graft (Peacock, 1959). Peacock injected a radioactive dye 
into the hind leg and measured the radioactivity over the various parts of the tendon 
20 minutes after injection. His study showed that blood vessels entering long 
tendons from the muscular origin and periosteal insertion are able to nourish only the 
proximal and distal third of the tendon. Circulation to the central third of long 
tendons is by intermediate vessels entering through disorganised paratenon or a 
definite volar mesentery. In free grafts this portion of the circulation is restored 
through postoperative adhesions, which appeared vital for the survival of the graft. 
 
Chaplin (1973) used microangiographic studies with barium sulphate injections 
(Chaplin, 1973). Chaplin’s studies demonstrated a difference in both the basic vascular 
pattern of intrasynovial and extrasynovial tendons and also in the pattern of 
revascularisation of these tendons. Following simple division intrasynovial parts of 
flexor tendons had no significant revascularisation. When used as free grafts all 
extrasynovial tendons showed good revascularisation and adhesion formation while 
intrasynovial tendon grafts retained their avascularity and adhesion occurred only at 
either ends of the graft. Chaplin concluded that extrasynovial grafts were inferior to 
intrasynovial grafts when used to repair damaged flexor tendons, as the vascularity 
seems to support adhesion formation. 
 
Sckell et al.  assessed the role of peritendinous tissue in the revascularisation of 
patellar tendon graft in a murine model using intravital microscopy (Sckell et al., 
1999). The peritendinous connective tissue envelope of the graft was completely 
removed, partially removed or not stripped at all. Intravital microscopy showed that 
grafts with intact peritendinous tissue showed accelerated vascularisation and 
histology confirmed higher viability compared to the other two groups. The authors 
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suggested that the intact connective tissue are either able to produce angiogenic 
factors or to stimulate host cells to generate and release these factors. 
 
Perfusion studies with India ink showed neovascularisation of extrasynovial tendon 
grafts through vascular adhesions by two weeks (Gelberman et al., 1992a). In 
contrast, the flexor tendon grafts of intrasynovial origin healed without ingrowths of 
vascular adhesions and neovascularisation took place from the proximal and distal 
sites of the sutures. Cross sections extrasynovial tendon showed obliquely oriented 
intratendinous vessel while intrasynovial tendons showed vessels extending through 
the surface layer of the tendon graft. 
 
Fenwick et al. reviewed the previous studies performed on tendon graft 
neovascularisation and concluded that neovascularisation is essential for the long-
term survival of tendon graft (Fenwick et al., 2002).  
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1.6 GFP species and animal selection for tendon grafting study 
 
A number of different species has been used to study various aspects of tendon graft 
healing. Many of these studies investigated the fate of tendon graft in the bone 
tunnel for Anterior Cruciate Ligament reconstruction.  With increase use of tendon 
grafts for overuse injuries several studies recently have investigated tendon to 
tendon grafting  
 
Table 1.4 - Animal models used for tendon grafting studies 
 
Animal Tendon graft for tendon repair 
studies 
Tendon graft for ligament 
reconstruction studies 
Mice (Hasslund et al., 2008; Zantop 
et al., 2006) 
 
Rat (Iwata et al., 2008; Kajikawa et 
al., 2008; Kajikawa et al., 2007; 
Tachiiri et al., 2010) 
(Bedi et al., 2009; Hays et al., 
2008; Kobayashi et al., 2005) 
Rabbit (Murphy et al., 2008) (Karaoglu et al., 2008; Lim et 
al., 2004; Ouyang et al., 2004) 
Avian (Ashley et al., 1964; Cao et al., 
2002) 
 
Porcine  (Lee et al., 2005; Liu et al., 
1995; Milano et al., 2006; Wu 
et al., 2009) 
Dog (Potenza, 1964; Seiler et al., 
1993b) 
(Shino and Horibe, 1991; 
Yasuda et al., 2004) 
Bovine  (Teli et al., 2005) 
Primate (Singer et al., 1989)  
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Canine models are popular for studying both tendon healing and tendon grafting 
biology due to their large size and anatomical similarity to human tendons (Potenza, 
1964; Seiler et al., 1993b). Larger animal models remain popular particularly when 
mechanical studies are planned (Shin et al., 2008; Singer et al., 1989). Requirement of 
genetically manipulable models have led to the increase in the use of rodent models 
(Chhabra et al., 2003). Mice and rat (Kajikawa et al., 2007; Kobayashi et al., 2005) are 
commonly used animals for tendon grafting studies and increase in their use is also 
aided by their low housing cost, large number of available antibodies, comparable 
properties to human tendons (Wong et al., 2006a).  
 
Transgenic species like GFP allow easy tracking of cells (Hadjantonakis and Nagy, 
2001; Kajikawa et al., 2007) in and out of grafts and has therefore become a popular 
technique to study grafting biology. (Hayashi et al., 2007; Matsuo et al., 2007; 
Muramatsu et al., 2007; Zantop et al., 2006). Some of the advantages of the GFP 
chimeric models are that they allow non invasive visualization and can be monitored 
real-time in vitro and in vivo and be quantified by flow cytometry, confocal 
microscopy and fluorometric assays (Hadjantonakis and Nagy., 2001). Moreover the 
availability of GFP BMT mice allows tracking of bone marrow derived cells in wounds, 
grafts etc therefore yielding useful information for tissue engineering (Zantop et al., 
2006 ; Kajikawa et al., 2007). GFP species has therefore become an effective tool to 
study the fate of grafted tissue and has shown tissue specific differences in grafting 
biology. 
 
The information available from various grafting studies using GFP animal models is 
summarized in table 1.5.
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Table 1.5- Use of GFP species for the study of grafting biology 
 
 
 
Author Species Specimen Tools used Main findings 
Iwata et al., 
2008 
GFP rat Achilles tendon graft 
to rotator cuff 
Confocal 
microscopy 
Graft cells disappear by 28 days and are 
replaced by host cells 
Muramatsu 
et al., 2007 
GFP rat Whole limb allograft 
and 
immunosuppression 
Fluorescent 
microscopy 
Tissue specific variation  in repopulation rate 
with skin cells repopulated first 
Kimura et al., 
2005 
GFP rat Sciatic nerve graft Fluorescent 
microscopy 
Retrograde transmigration of donor cells-
contributing to axonal regeneration in the 
recipient nerve 
Matsou et al., 
2007 
GFP 
mice 
Skin graft Immuno- 
histochemistry 
Rejection of full thickness dorsal skin graft. 
Improved viability with tail skin grafts 
Keijser et al., 
2006 
GFP rat Cornea- limbal 
isograft, sibling 
allograft and 
nonsibling allograft 
Fluorescence 
microscopy and 
Immuno- 
histochemistry for 
macrophage and 
lymphocyte 
Average transplant survival 143 days 
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1.7 Role of cells in engineered tendon 
 
Controversy surrounds the value of grafting of cell- based constructs in tendon and it is 
still unclear as to whether the cells in a tendon graft remain viable after the grafting 
procedure. It has been argued that cells are not necessary for healing of transplanted 
tendon (Hasslund et al., 2008) or construct (Badylak et al., 1999) as host cells would 
eventually repopulate them and that it  would simplify the immunogenic aspect of 
construct transplant. On the other hand cell based constructs have been reported to 
have improved mechanical function than cell free constructs (Butler et al., 2004). Liu 
reported formation of structurally disorganised neo-tendon in the scaffold only group 
and concluded that an even distribution of cells is required in donor tendon/construct 
to form a homogenous tissue (Liu et al., 2006). The precise nature of cellular traffic into 
grafts or out of grafts is still largely unknown.  
 
Tendon engineering has advanced significantly in the past 25 years. But one of the main 
limitations of engineered tendons is that their mechanical strength still remains much 
lower than that of a normal tendon (Butler et al., 2008; Liu et al., 2006). One potential 
means of improving collagen deposition and improving collagen alignment which in 
turn could influence recruitment of tendon strength would be to investigate tendon 
progenitor cells in a construct. Previous studies have shown that embryonic and 
neonatal tendon fibroblasts deposit collagen in parallel alignment through cytoplasmic 
protrusions termed “fibripositors” (Canty et al., 2004; Canty et al., 2006). These cells 
can be isolated from embryonic tendon and cultured in vitro. Furthermore, it has been 
demonstrated that these cells form a “neo-tendon” when under tension in the absence 
of a blood supply (Kapacee et al., 2008). 
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Figure 1.9 - Electron microscopy of fibripositor positive tendon construct. (a) Transverse section of a 
metatarsal tendon from a 13-day chick embryo showing fibripositors (red arrow) and a fibricarrier (blue 
arrow), (b) Embryonic tendon cells (ETC) in a construct 1-week post contraction, (c) Electron microscopy 
of ETCs on Aclar, (d) Disorganised arrays of thin filaments 1-week after severing a construct. Scale Bars - 
500 nm (Kapacee et al., 2008) 
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1.7.1 Cell-free tendon constructs 
 
Many scaffold based materials are under investigation as tendon replacement material. 
One successful biomaterial that has already been marketed is the extracellular matrix of 
porcine small intestinal submucosa (SIS-ECM).  SIS-ECM has been used to repair Achilles 
tendon (Badylak et al., 1995; Derwin et al., 2004), rotator cuff  (Dejardin et al., 2001; 
Iannotti et al., 2006)and flexor tendon (Derwin et al., 2004) and has been shown to 
regenerate neo-tendon with limited mechanical recovery.   
 
1.7.2 Cell based tendon constructs 
 
Numerous cell types have been investigated as potential cell based therapies in tendon 
grafting. Kryger investigated 4 cell lines  (epitenon tenocytes, sheath fibroblast, bone 
marrow derived mesenchymal stem cell and adipoderived stem cell) and showed that 
all grafts had been populated by cells (Kryger et al., 2007). However it was unclear from 
these studies where the cells came from, whether the graft cells undergo apoptosis or 
remained viable due to the limitations of histological staining. These findings suggest 
that more work is required to identify whether cells migrate into the tendon, or are 
replaced, and whether apoptosis or cell migration is involved.  
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1.8 Summary 
 
A review of the literature suggests that though some histological data exist regarding 
the fate of tendon grafts no   study has been done so far to identify the role of the graft 
cells.  Cell based therapy offers an exciting potential for the future of tendon healing 
and therefore a better understanding of the grafting biology may open new therapeutic 
possibilities. On the other hand it may also help us to understand and improve on 
current tendon grafting practices. A single report was found where tendon to tendon 
grafting was studied using transgenic animals (Iwata et al., 2008) to investigate 
persistence of fluorescence of grafted GFP tendon. Another study used wild type mice 
as a tendon grafting model (Hasslund et al., 2008) focussing on adhesion and growth 
factor profile during graft healing. Neither study investigated the role of the grafted 
cells in healing and the mechanism of cellular repopulation. Though earlier histology 
based experiments suggested that the graft remain alive and healing occur from the 
stump cells, newer evidence suggests that repopulation by host cells may play a major 
role in graft integration. A more detailed study looking into the activity of graft cells at 
various stages of healing will be undertaken to clarify these controversial points of 
interest. 
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1.9 Aims 
 
1) To establish a model for the study of tendon grafting  
2) To study the fate of graft cells after tendon grafting 
3) To study the chronological events of  tendon graft take 
4) To identify the applicability of the model for testing of tendon constructs 
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Chapter two 
Materials and methods 
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2.1 Experimental animals 
 
The availability of large numbers of transgenic and knockout species   makes the mouse 
a useful research model.  For this study two varieties of transgenic mice species were 
chosen- the C57BL/6J and the enhanced Green Fluorescent Protein (eGFP) expressing 
mice C57BL/6-Tg (CAG-EGFP)1 Osb/J. The C57BL/6J mice are the most widely used inbred 
strain and the first to have its genome sequenced 
(http://jaxmice.jax.org/strain/000664.html).  The GFP mice was generated in C57BL/6 
mice with an "enhanced" GFP (eGFP) cDNA under the control of a chicken beta-actin 
promoter and cytomegalovirus enhancer which makes all of the tissues, with the 
exception of erythrocytes and hair, appear green under excitation light (Ikawa et al., 
1995). C57Bl/6J mice and eGFP (commonly referred to as GFP in publications) mice were 
chosen to carry out transgenic grafting as the two strains are identical except for the 
transgene, have only a small number of reported rejections and have easily available 
antibodies for the detection of the GFP. 
 
Both the   C57 BL/6J and GFP mice were supplied by Harlan (Blackthorn, Oxfordshire) 
and housed at   the Biological Unit, in the University of Manchester. Male mice aged 8-12 
weeks were used for the study. Mice were matched on size and weight for grafting. 
Mice were housed together prior to surgery and individually after the surgical 
procedure. They were provided with mashed   feed for the first week in order to 
prevent weight bearing on operated hind limbs. Standard recommended husbandry 
was provided by the technical staff at the biological unit. 
52 
 
 
 Table 2.1- Number of animals used  
 
 
 
 
 
 
 
 
 
 
 
 
 Type of study Number of mice 
Mouse Achilles tendon 
anatomy study 
C57Bl/6J 16 
GFP 8 
Transgenic grafting study C57Bl/6J 12+3 (for graft 
harvest) 
 
GFP 12+4 
Construct grafting studies C57Bl/6J 12 
 GFP 8 
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2.2 Method of anatomical characterisation of mouse Achilles tendon 
 
2.2.1 Macroscopic anatomy 
 
8 c57BL/6Jmice legs (4 left and 4 right) were viewed and dissected under a Leica MZ6 
stereomicroscope (Leica Microsystems Ltd, Switzerland) using surgical micro 
instruments Dissected samples were kept moist by regular spraying with pH neutral 
phosphate buffered saline (PBS) (Sigma-Aldrich Company Ltd, Poole, UK). 
 
2.2.2 Microscopic anatomy 
 
8 legs (4 left and 4 right) of C57BL/6J and 8 legs (4 left and 4 right)  of GFP  mice were 
collected immediately after termination and fixed in fresh Zinc fixative solution 
(Appendix) for 48 hours at 4°C prior to transfer to 50% Industrial Methylated Spirit (IMS) 
(Genta Medical, York, UK) solution for preservation.  16 legs   were then decalcified in 
20% pH 7.4 EDTA solution (Tennants Brewery, Manchester, UK) (Appendix) for 15 days 
with solution changes every 5 days. Radiographs were performed on the 15th day to 
ensure complete decalcification. This was achieved by placing samples over unexposed 
9 x 12 centimetre Industrex C radiograph film (Kodak, Rochester, New York) in black 
plastic wallets into a lead enclosed dental radiograph machine (Faxitron, Illinois, USA).  
The power settings were set to 45 kVp and the sample was exposed to 5 seconds worth 
of radiation. The radiograph machine was deactivated and the radiographic film was 
developed in a dark room with 3 minutes in Phenisol developer solution (Ilford Imaging 
ltd, Mobberley, England.) followed by 3 minutes in running cold water. The film was 
then placed in Hypam fixer solution (Ilford Imaging ltd, Mobberley, England.) for 3 
minutes then further rinsed for 3 minutes in cold running water prior to leaving to air 
dry. Following decalcification the decalcified legs were put back into 50% IMS solution 
until further processing. Remaining  8 C57BL/6J (4 left and 4 right) mice legs and  8 GFP 
(4 left+ 4 right)  legs were filleted to remove the bone from the specimen and 
immersed in 50% IMS.  
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Both the decalcified legs and filleted legs were processed in a Tissue-Tek Vacuum 
Infiltration Processor (Bayer Diagnostics, Newbury, Berkshire, UK) on a skin cycle 
program (Appendix). Following wax processing, legs were placed in wax wells that 
were filled with molten wax. Legs were positioned in either longitudinal alignment or in 
an axial alignment and left for the wax to set over 24 hours. The blocks were cut at 7 
μm sections from paraffin embedded samples using a HM 335E electronic microtome 
(Microm, Walldof, Germany) using Accu Edge low profile disposal blades (Feather 
Safety Razor Co Ltd, Japan). Sections were floated on a warm water bath (37-40˚ C) and 
mounted on coated 1% poly-l-lysine slides (Cell Path). The sections were dried briefly on 
a hot plate prior to being labelled and placed into an oven overnight at 37˚C.  
 
2.2.2.1 Basic staining-Haematoxylin and eosin 
 
Haematoxylin & Eosin staining (Appendix) was used to highlight cell nuclei purple 
(Harris alum haematoxylin) and counter stain remaining tissue pink (Eosin 
Y)(Appendix). Following dewaxing, sections were placed into filtered haematoxylin for 
4 minutes followed by a period of “bluing” which involves rinsing in running tap water 
for 5 minutes. Slides were subsequently transferred to Eosin Y for 30 seconds followed 
by rinsing in running water for 10 seconds and dehydrated through the alcohols prior to 
mounting in Pertex and glass cover slips.  
 
2.2.2.2 Alcian Blue Staining 
 
This stain highlights acid mucosubstances (Glycosaminoglycans) and acidic mucins that 
were used to highlight  fibrocartilaginous areas within tendon. Sections were dewaxed 
and hydrated then placed in Alcian Blue Solution pH 2.5 (which stains weakly sulphated 
mucins-Appendix) for 5 minutes. Samples were then washed in tap water followed by 
counterstaining in 0.1% Nuclear Fast Red (Appendix) for 5 minutes. Further washing in 
tap water was performed and slides were then dehydrated and mounted with Pertex 
and glass cover slips. 
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2.2.2.3  Miller’s Elastin 
 
This stain highlights elastin fibres. Sections were dewaxed and hydrated through 
graded alcohols and then treated in 0.5% acidified Potassium Permanganate (Appendix) 
for two minutes then rinsed in tap water prior to washing in 95% IMS. Sections were 
then placed into Miller’s Elastin Staining   solution for two hours and then washed in 
95%  IMS solution. Counterstaining was performed in Van Gieson’s stain (Appendix) for 
2 seconds prior to washing and dehydrating through the alcohols and mounting in 
Pertex and glass cover slips. 
 
2.2.2.4 Masson’s Trichrome Staining 
 
Masson’s Trichrome stain (Appendix) for collagen and other components of the 
extracellular matrix. Slides were dewaxed and rehydrated followed by submersion in 
Harris’ Haematoxyllin for 4 minutes and bluing for 5 minutes. Samples were  then 
transferred to 1 % (v/v) picric acid for 30 seconds, rinsed in running water until only a 
yellow tint remained for 1 minutes, transferred to 0.1 % (w/v) Biebrich scarlet for 2 
minutes and then quickly rinsed in water for 10 seconds.  Slides were then placed into 
50% phosphomolybdic acid/50% phosphotungstic acid (50:50 PMA/PTA) for 10 minutes 
then transferred directly to Fast Green for 5 minutes and rinsed in tap water for 10 
seconds. The slides were dehydrated and mounted with Pertex and glass cover slips. 
 
2.2.2.5 Hoechst and Phalloidin stain 
   
Slides were dewaxed, rehydrated and rinsed in 0.1% Triton X-100 in PBS three times, five 
minutes each. Sections were incubated for one hour with of TRITC-labelled phalloidin 
(1:500 dilution, Sigma, Dorset, UK). Slides were then rinsed again and incubated with 
Hoechst 33258 bisbenzimidazole nuclear counterstain (1:500 dilution) for 30 min. After 
one further rinse, sections were mounted in Gelvatol anti-fade aqueous mountant. 
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2.2.2.6  Immunohistochemistry with Alpha Smooth Muscle Actin ( Alpha 
SMA) 
 
Alpha Smooth Muscle Actin (αSMA) is expressed by pericytes which are cells present in 
the endothelium of blood vessels. Experimental  and control slides were selected  and 
rehydrated through xylene and graded alcohols (5 minutes in xylene twice, then 10 
seconds in each graded alcohol 100% -> 100% ->90% ->70% -> 50% -> PBS)  and then 
washed in PBS-Tween twice for 5 minutes each time. Sections were immersed in 3% 
H202 solution for 10 minutes and washed again in PBS- Tween (.01%) twice for 5 minutes 
each time. Sections were dried and segregated with ImmEdge Hydrophobic Barrier Pen 
(Vector Lab) and then washed in PBS tween for 5 minutes.  Horse blocking serum (2.5%) 
was added to all sections (Immpress-Vector Lab) and incubated for 30 minutes. 
Sections were washed in PBS-tween twice for 5 minutes. Primary antibody (Rabbit 
polyclonal-Abcam) were added to alternate sections and incubated at 37˚C for 1 hour. 
PBS was added to rest of the sections. The slides were washed twice in PBS-Tween and 
ImmPRESS anti-rabbit Ig (Immpress-Vector lab)) was added to all sections and 
incubated at 37°C for 30 minutes. The slides were washed in PBS twice for 5 minutes 
and then 3, 3’-diaminobenzidine (DAB -Vector Lab) solution was added to each section 
for 5 minutes minimum or until DAB precipitated, rinsed in PBS twice for five minutes, 
counter stained in Nuclear fast red for minimum of five minutes, dipped in water twice 
and dehydrated through graded alcohols and into clean xylene twice for 5 minutes and 
mounted in Pertex and dried. 
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 2.3 Tendon Grafting 
 
 2.3.1 Operative procedure for tendon grafting  
 
4 GFP and 4 C57BL/6 mice were used for each time point. Graft harvested from the GFP 
mouse was applied to a defect in the C57 BL/6 mouse Achilles tendon as an onlay or 
patch graft using one securing sutures on each end to minimise trauma and handling 
(Figure 2.1- 2.2). Similarly graft harvested from the C57 BL/6 mouse was placed into the 
GFP mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1- Diagrammatical representation of design of syngenic and autologous grafting showing the 
C57BL/6 mouse receiving a  green GFP graft (above) and the green GFP mouse receiving a C57 BL/6 graft 
(below) 
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All equipment and instruments were checked thoroughly prior to surgery. Anaesthesia 
was induced by 4% Isoflurane (Abbott Laboratories, UK) and Oxygen (BOC) at 4 
litre/minute and maintained by 2% Isoflurane and Oxygen at 2 litre/minute, with an 
Oxygen drive. 
 
Achilles tendon was harvested from freshly euthanized donor mice under magnification 
(Leica Surgical microscope). The donor tendon was placed in CO₂ independent media 
(Gibco-Invitrogen) to maintain viability during transfer. 
 
 
 
 
 
 
 
 
 
   
 
 
          
Figure 2.2- Diagrammatic representation of surgical technique of tendon grafting studies showing 
placement of the graft in a 50% defect of the tendon and the placement of the proximal and distal holding 
sutures 
 
The recipient mouse was   placed in prone position on a custom made operating table 
made of thermoplastic material.  The legs were shaved and hair removed with a 
handheld vacuum cleaner. The area was cleaned with Hibiscrub (Chlorhexidine 
Gluconate 4% w/v-Molnlycke Health Care). The left leg was stretched out, immobilized 
with blue tack (Bostik, UK) underneath and over the foot( Figure 2.3- 2.4).  A tourniquet 
was applied at the thigh using elastic ribbon. A 1 cm longitudinal incision was made at 
the midposterior line on the back of the right leg from the musculotendinous junction 
       Recipient tendon 
        GFP graft 
       Autologous graft 
       Sutures 
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to just distal to the ankle joint. The direction of plantaris was confirmed by its insertion 
into the plantar aponeurosis. The plantaris was separated from the body of the Achilles 
tendon by sharp dissection of their fascial connections. A distal transverse incision was 
made in the Achilles tendon comprising 50% of the width of the tendon. The incision 
was extended longitudinally up to 4 mm and then the segment was divided proximally. 
In the left leg, the donor tendon placed in media previously (GFP tendon graft to C57 
mice and C57 tendon graft to GFP mice) was placed into the defect and secured with 10-
0 polyamide (Braun Medical, UK) sutures proximally and distally. Fascia and plantaris 
were replaced back into position. The tendon was kept moist and well hydrated with 
regular normal saline irrigation. Skin was closed with 8-0 interrupted suture. 
Subcutaneous Buprenorphine (Reckitt Benckiser Healthcare, UK-Appendix) was 
administered to all animals for postoperative analgesia. 
 
In the left leg, a cut segment from the same tendon was put back into the defect as 
autologous graft. Mice were weighed and recovered in individual cages with standard 
animal husbandry. 
 
After the procedure mice were monitored carefully on a daily basis. Weight, ambulation 
and wounds were recorded. The mice generally had excellent postoperative recovery 
and was fully weight bearing within 24 hours. No clinical signs of rejection were noted 
at any stage. 
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Figure 2.3 -Photographic representation of surgical procedure for tendon grafting showing  i) 
Positioning of mouse leg , ii) Longitudinal incision for exposure, iii) Exposed Achilles tendon (iv) 
Achilles Tendon separated from surrounding tissue (v) Distal 50% transverse cut  and  vi) Excising a  
50% segment of tendon. Scale Bar-3 mm 
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Figure 2.4 -Photographic representation of surgical procedure for tendon grafting showing -i) 50% cut 
segment of the Achilles tendon, ii) Syngenic  or autologus graft placed in the defect, iii) proximal suture, 
iv) distal suture to secure graft, v) continuous suture for skin closure, vi) skin closed; Scale Bar-1 mm 
i ii 
iii iv 
v vi 
62 
 
2.3.2 Tissue Harvest 
 
4 GFP and 4C57BL/6 (n=8) mice that had underwent tendon grafting procedures were 
harvested at each of the following time point- Day 3, Day 21 and Day 90 (total n=24). The 
time points were chosen in keeping with the three classic stages of healing- 
inflammation, proliferation and remodelling. 
 
Mice were euthanized by an overdose of CO2 inhalation followed by cervical 
dislocation. The legs were removed at the knee joint. Longitudinal incisions were made 
on the medial and lateral side of the leg for better penetration of fixatives. The 
specimens were submerged in a Zinc based fixatives for a minimum of 48 hours and 
then changed into 50% IMS until further processing. 
 
Hair was removed by application of hair removal cream for 20-30 minutes and then 
washed in PBS and re-submerged in 50% IMS. The posterior compartment of the leg was 
sharply filleted. The excised specimen was carefully assessed for residual bone 
fragments. 
 
2.3.3 Tissue processing 
 
All fixed samples were processed in a Tissue-Tek Vacuum Infiltration Processor (Bayer 
Diagnostics, Newbury, Berkshire, UK) on a skin cycle program (Appendix). Following 
wax processing legs were placed in wax wells that were filled with molten wax. All legs 
were carefully positioned to allow for longitudinal sections. The wax blocks were left to 
set over 24 hours.  
                       
7μm sections were cut from paraffin embedded samples using a HM 335E electronic 
microtome (Microm, Walldof, Germany) using Accu Edge low profile disposal blades 
(Feather Safety, Japan). Sections were floated on a warm water bath (37-40˚ C) and 
mounted on 1% poly-l-lysine (Cell path, UK). The sections were dried briefly on a hot 
plate prior to being labelled and placed into an oven overnight at 37˚C. 
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2.3.4 Histology for tendon graft characterisation 
 
2.3.4.1 Dewaxing 
 
Before staining, the paraffin embedded sections were immersed in two consecutive 
xylene (Genta Medical, York, UK) baths for 5 minutes to dissolve wax. Then slides were 
transferred to consecutive solutions of 100% IMS, 100% IMS, 90% IMS, 70% IMS then 50% 
IMS for 10 seconds each to rehydrate samples. 
 
2.3.4.2 Dehydrating and slide preservation 
 
Following staining slides were transferred to consecutive solutions of 50% IMS, 70% IMS, 
90% IMS, 100% IMS, and 100% IMS for 10 seconds each. The slides were then placed into 
two consecutive xylene baths for 5 minutes each prior to coating with Pertex mounting 
media (Cellpath plc, Powys, UK) and 50mm x 22mm glass coverslips  (Scientific 
laboratory supplies Ltd, Nottingham, UK) and allowed to dry at room temperature 
before light field microscopy.  
 
2.3.4.3 Haematoxylin and eosin staining (H & E) 
 
Haematoxylin and Eosin staining was performed on every 4th slide for orientation. 
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2.3.5  Immunohistochemistry 
 
Table 2.2 shows list of antibodies that were used to identify the types of inflammatory 
cells, presence of GFP cells, collagen synthetic activity, proliferative activity, apoptosis 
and vascularisation.  
 
Table 2.2 - List of antibodies used and their targets 
 
Antibodies Function 
CD45 Pan Leukocytic marker 
Ly6G Predominantly Neutrophil  and subset of Eosinophil 
F4/80 Mature tissue macrophages and activated macrophages 
CD3 T-lymphocytes 
Alpha SMA Pericytes in blood vessels 
BrdU 5-Bromo-2-deoxyuridine-Thymidine analogue 
incorporated into newly synthesizing DNA of replicating 
cells. Antibody to BrDU can then be used to detect this 
Hsp47 Heat Shock Protein 47- A molecular chaperone that 
interacts with and stabilizes procollagen 
TUNEL Terminal-deoxynucleotidyl Transferase Biotin dUTP End 
labelling for DNA fragment-marker for apoptotic cells 
GFP GFP positive cells 
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Table 2.3 - Antibodies and their pre-treatment, primary, secondary, 
amplifier and chromogens used 
 
Antibody Pre-
treatment 
Block Primary Secon 
dary 
ABC DAB Control 
CD 45  
(BD 
Pharmingen) 
None 1% rabbit 
serum 
1:100 
Rat anti-
mouse 
1:200 
rabbit 
anti- rat 
Yes Yes Spleen 
Ly6G 
(BD 
Pharmingen) 
None 1% rabbit 
serum 
1:200 
Rat anti-
mouse 
1:200 
rabbit 
anti-rat 
Yes Yes Skin 
wound 
F4/80 
(Serotec) 
None 1% rabbit 
serum 
1:200 
Rat anti-
mouse 
1:200 
rabbit 
anti- rat 
Yes Yes Spleen 
CD3 
(BD 
Biosciences) 
None 1% rabbit 
serum 
1:200 
Rat anti-
mouse 
1:200 
rabbit 
anti- rat 
Yes Yes Spleen 
Alpha SMA 
(Abcam) 
Ab5694-100 
None 2.5% Goat 
serum 
1: 200 
Rabbit 
polyconal 
Immpress 
kit(Vector 
Lab) 
 No Yes Spleen 
Hsp 47 
(Stressgen) 
None MOM 
block 
1:200 
Mouse  
Monoclonal 
MOM kit 2 
IgG  
Yes Yes 
 
Skin 
wound 
BrdU 
(Abcam) 
10 min in 4 
M HCl, 10 
min in 
borate 
buffer 
1% rabbit 
serum 
1:200 
Rat anti- 
mouse 
1:200 
rabbit 
anti-rat 
Yes Yes Spleen 
TUNEL 
(Roche) 
 30 min in 
Tris HCl+ 
Proteniase K 
None 2:3 -enzyme: 
solution 
1:2:1 sheep 
serum: 
PBS: POD 
kit 
No Yes Large 
intestin
e 
GFP 
(Abcam) 
None 1% Rabbit 
serum 
1:200 
Rat anti-
mouse 
1:200 
rabbit 
anti-rat 
Yes Yes GFP 
spleen 
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2.3.5.1 Protocol for GFP antibody staining  
 
 Slides were dewaxed in Xylene twice for 5 minutes each  and then  rehydrated through 
descending alcohol-100%, 100%, 90%, 70% and  50%, 5 seconds in each  and then washed 
in water for 30 seconds . They were then washed in PBS-Tween (Appendix) three times 
for 5 minutes each and gently stirred on a shaker during all washes. Endogenous 
peroxidase activity was blocked by using 3% H2O2 (made from 30% H2o2-Sigma) for10 
minutes and the washed again in PBS-Tween twice for 5 minutes.  Slides were dried 
individually in between sections and sections were separated using a wax pen 
(Immedge- Vector Lab) to allow the solution to stay on the section and separate them 
from controls. The wax was allowed to dry and then washed twice again in PBS-Tween 
to remove any excess wax. 1% rabbit serum was used to block nonspecific antigens and 
35μl of blocking serum was added to each section. Alternate sections in the slide were 
used as negative control and GFP spleen was used as positive control. The slides were 
incubated with blocking serum for one hour at room temperature and then washed 
again in PBS-Tween x 2 for 5 minutes. Primary antibody (Sheep anti-mouse) was added 
to experimental sections in 1:100 dilutions and blocking serum was added to control 
sections. Slides were incubated at 4 degrees overnight and washed in PBS-Tween x 2 
for 5 minutes. Slides were gradually rewarmed to room temperature and secondary 
antibody (Rabbit anti-sheep) at 1:200 dilutions were applied to all sections and 
incubated at 37 degrees for one hour. Slides were then washed in PBS twice for 5 
minutes, ABC was (Avidin Biotin Complex) added to all sections and incubated for 30 
minutes in room temperature and then washed in PBS for 5 minutes twice. DAB (Vector 
Lab) was added for 5-8 minutes or until change of colour and then washed in PBS twice 
for 5 minutes each. The slides were counterstained with nuclear fast red for 10 minutes, 
then dipped in water, dehydrated through ascending alcohol 5 seconds each in 50%, 
70%, 90%, 100%, 100% alcohol and in  Xylene twice for 5 minutes. All slides were mounted 
in Pertex with coverslip and left overnight to air-dry.  
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2.3.5.2 Immunostaining for Inflammatory markers 
 
A similar protocol was followed for inflammatory marker immunostaining with the 
exception of application of primary antibodies (Figure 2.5) and a rabbit anti-rat 
secondary. Three of the four sections of the slide were incubated with a different 
primary antibody at 37˚ overnight while the 4th control section received no primary. 
 
 
                   
                             
 
          
 
 
 
 
 
 Figure 2.5 - Diagrammatic representation of   a slide showing immunostaining   for inflammatory markers 
using serial sections of the same slide 
 
 
       CD45 
       F4/80 
       Ly6G 
       Control 
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2.3.5.3 Immunostaining for Cellular activity markers- Proliferation, 
collagen synthesis, apoptosis, vascularisation (Pericyte) 
 
Experimental  and control slides were selected  and rehydrated through xylene and 
graded alcohols (5 minutes in xylene twice, then 10 seconds in each graded alcohol 100% 
-> 100% ->90% ->70% -> 50% -> PBS)  and then washed in PBS-Tween twice for 5 minutes 
each time. Sections were immersed in 3%H202 solution for 10 minutes and washed again 
in PBS- Tween twice for 5 minutes each time. All slides had a minimum of four sections 
on them. Sections were dried and segregated with a wax pen and then washed in PBS-
Tween for 5 minutes.  
 
 
       
 
 
 
 
 
 
 
 
Figure 2.6 - Diagrammatic representation of a slide showing immunostaining for proliferation, synthesis, 
apoptosis and vascularisation using serial sections of the same slide 
 
Slides were placed in the incubator and two drops of 4M HCL were added to the top 
section only and left for 10 minutes. PBS was added to the rest of the sections. Slides 
were quickly rinsed in PBS and then two drops of borate buffer were applied to the   
top section of each slide only and left for 5 minutes. Slides were washed again twice in 
PBS-Tween for 5 minutes. Blocking solution was added to BrdU (1% Rabbit serum), Hsp 
47 (MOM Blocking agent) and Alpha-SMA (ImmPRESS) sections and PBS to TUNEL 
sections and left for30 minutes. After 30 minutes proteinase k (Roche, UK) in Tris HCL 
       BrdU 
       Hsp47 
       α-SMA 
       TUNEL 
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solution was added to TUNEL sections. Sections were washed in PBS-Tween twice for 5 
minutes. Primary antibodies were added to the sections (Figure 2.6) and incubated at 
37˚C for 1 hour. The slides were washed twice in PBS-Tween and secondary antibody 
was added firstly to BrdU (Rabbit anti-rat) and Hsp47 (MOM secondary) for 30minutes 
and kept at room temperature. Sections were washed in PBS-Tween twice for 5 
minutes and ABC was added to BrdU and Hsp 47 sections, ImmPRESS to SMA sections 
and POD development kit to TUNEL and incubated at 30°C for 30 minutes. The slides 
were washed in PBS twice for 5 minutes and then DAB solution was added to each 
section for 5 minutes minimum or until DAB precipitated, rinsed in PBS twice for five 
minutes, counter stained in Nuclear fast red for minimum of five minutes, dipped in 
water twice and dehydrated through graded alcohols and into clean xylene twice for 5 
minutes and mounted in Pertex and dried. 
 
2.3.6 Image capture 
 
Gross anatomical structures were captured using a Nikon Coolpix 4500 digital camera 
(Nikon, Japan) mounted on Leica M650 operating microscope (Leica, Germany). Files 
were captured at 2272 x 1704 pixels of resolution and saved as uncompressed .tiff files.  
Histological images were captured on a Leica DMRB microscope for direct transmission 
brightfield microscopy with a mounted Spot RT digital camera. Images were captured 
using Spot advanced capture software version 3.1 (Diagnostic Instruments, Inc., MI, 
USA) on a Silicon graphics Pentium III 230 mhz PC and saved as uncompressed .tiff files 
prior to transfer to external hard drives. 5x and 10x   objectives were used to magnify 
images.  
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2.3.7 Image analysis 
 
All images were montaged and aligned in Adobe Photoshop CS5 (Adobe Systems Inc. 
USA). Standard sized areas were selected in the graft tendon, host tendon and in the 
subcutaneous tissue using adobe Photoshop (n=3 slide/mouse/ stain).  A total of 12 (3 
slides/mice x 4 mice/time point) slides per time point were analysed for each stain. For 
quantitative analysis, Individual cells showing markers of inflammation, proliferation, 
synthesis or apoptosis were counted using the cell counter in the Image J software 
(http://rsbweb.nih.gov/ij). Data was put into Microsoft excel data sheet and analysed 
using SPSS version 16 (SPSS Inc. Chicago, USA). Three dimensional reconstructions of 
serial sections were done using “Reconstruct” software (“Reconstruct” by John C. 
Fiala). 
 
2.3.8 Statistics 
 
Mean values were calculated using SPSS version 16 (SPSS Inc. Chicago, USA) and 
expressed with the standard error of means following “±” symbol. The Kolgomorov-
Smirov test was used to show that the data were normally distributed.  Independent T 
testing was used to analyse differences between autogenic and syngenic grafting 
biology. Differences in cellular biology between control and different time points were 
assessed by analysis of means using one-way ANOVA and post hoc Tukey test. In all 
cases p value was considered significant if below 0.05. Significance was recorded with * 
in the graph if p-value was   less than 0.05 and   ** if p was less than 0.001. 
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2.4 Application of The mouse Achilles Tendon   model for Biomaterial 
Testing 
 
Two different varieties of engineered tendon constructs were   investigated using the 
mouse Achilles tendon model. One was a GFP positive  cell based construct developed 
by a collaborative group using techniques described by Kapacee et al (Kapacee et al., 
2008). The second construct was   Polycaprolactone 3D electrospun bundles, an 
acellular biocompatible construct developed by Downes Lab at the material Science 
centre  at the University of Manchester. 
 
2.4.1 Cell Based  Fibrin Construct 
 
Cells were extracted from 3 weeks old GFP mouse tail tendon with trypsin (37,000 U) 
and bacterial collagenase. Each well   of a six well plate was coated with a 2 mm-thick 
layer (1.5 ml) of SYLGARD In each well. Fixed-position posts were created by pinning 
minutiens insect pins. Cells were suspended in fibrinogen and thrombin and incubated 
at 37 °C in DMEM4 supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), L-
glutamine (2 mM), L-ascorbic acid 2-phosphate (200 mM), and 10% fetal calf serum. The 
plates were scored every 2 days to release fibrin gel that had adhered to the SYLGARD. 
The Cells   contracted   the fibrin gel during   6 days and formed a tendon like structure 
(Figure 2.7). 
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Figure 2.7 Formation of a construct from embryonic tendon cells. (a) plan view of a fibrin gel during 
contraction. The black arrow shows the outer edge of the gel. (b) plan view of a fully-contracted gel 
(black arrow), White arrows point to short lengths of suture material attached by minutien pins (c) 
transverse section of a construct 1-week post contraction stained with toluidine blue (d) longitudinal 
section of a construct 1-week post-contraction stained with haematoxylin-eosin showing the parallel 
alignment of cells. Scale Bar- 50 µm (Kapacee et al., 2008). 
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2.4.2 Acellular Construct  Polycaprolactone  3D electrospun bundles  
 
Acellular Polycaprolactone 3D electrospun (PCL) bundles were supplied by a 
collaborative group. The material has previously been tested as a peripheral nerve 
conduit (Sun et al., 2010). 
 
The bundles had a low melting point of 50˚C and therefore attempts at testing them 
with wax sections failed. The specimens were tested with Scanning Electron 
Microscopy (SEM) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 – Scanning Electron Micrograph demonstrating the structural morphologies of 3D fibrous 
bundles fabricated by the techniques described in the appendix – fine mandrel. ( Magnification x 500). 
Photpgraph by Lucy Bosworth 
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2.4.3  Surgical Procedure for in vivo contsruct testing 
 
The recipient mouse was placed in prone position in the operating board. The legs were 
shaved and hair removed with a handheld vacuum cleaner. The area was cleaned with 
Hibiscrub (Chlorhexidine Gluconate 4% w/v-Molnlycke Health Care). The left leg was 
stretched out, immobilized with blue tac (Bostik, UK) underneath and over the foot. 
Tourniquet was applied at the thigh using elastic ribbon. A 2 cm longitudinal incision 
was made at the midposterior line on the back of the right leg from the 
musculotendinious junction to just distal to the ankle joint. The direction of plantaris 
was confirmed by its insertion into the plantar aponeurosis. The plantaris was 
separated from the body of the Achilles tendon by sharp dissection of their fascial 
connections. A distal transverse incision was made in the tendon comprising 50% of the 
width of the tendon. The incision was extended longitudinally up to 4 mm and then the 
segment was divided proximally.  
  
The cell based fibrin construct was cut at both ends, lifted from its culture media and 
was trimmed to the size of the defect. Either a fibrin construct or an a acellular PCL 
construct was  placed  into the defect and secured with 10-0 polyamide (Braun Medical, 
UK) sutures proximally and distally. Remaining part of the surgery was carried out as 
described for tendon grafting surgery.  
 
In the PCL construct study mice (n=6, 2 mice/time point) were harvested at the 
following time points- Day 0, Day 3 and Day 21. At the time of harvest, mice were 
euthanized and the left leg dissected with the Achilles tendon removed from the bone. 
The tissue was stored in zinc fixative. The initial and final time-points were analysed by 
variable pressure SEM (VPSEM) (Zeiss), which allowed tissue samples to be viewed 
without dehydration and gold sputter-coating. An accelerating voltage of 5 keV was 
used to scan the tissue surface. 
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In the fibrin construct study a shorter time course was chosen to determine persistence 
of construct. Mice were harvested at Day 0, Day 3 and Day 7 (n=2/time point). The legs 
were processed using the same methodology described for syngenic grafting studies. 
 
 
 
 
 
 
Figure 2.9 -Fibrin construct  in vivo testing- (i) Construct lifted from culture into the wound, (ii) 
Construct being secured with a proximal suture and (iii) a distal suture (iv) Construct secured in 
tendon defect; Scale Bar- 1 mm. 
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Figure 2.10 -Acellular PCL construct  in vivo testing- (i) Defect being created in the wound, (ii) PCL 
Construct placed into the wound (iii) Construct being secured with a proximal suture and (iv) a distal 
suture, Scale Bar= 1 mm 
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Chapter Three 
Results 
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3.1 Results- Anatomical characteristics of Mouse Achilles tendon 
 
3.1.1. Macroscopic Anatomy  
 
The Achilles tendon is formed by the union of the tendons of gastrocnemius and soleus 
(Figure 3.1). The average length of the tendon (from musculotendinous junction to 
calcaneal insertion) is 0.63 ±0.10 mm. The tendon is closely related on its posterior and 
medial aspect to the tendon of plantaris which travels from the medial side of the 
tendon to lie at its posterior aspect and passes over the posterior surface of the ankle 
to insert into the plantar fascia in the sole (Figure 3.2). The plantaris tendon was found 
to be present in all experimental animals and cadavers. The Achilles tendon spirals in its 
long axis and the medial fibers become posterior distally. The tendon consistently 
received contribution from both the soleus and the gastrocnemius muscles and 
tendons. 
 
Anteriorly there is an obvious plane of demarcation between the superficial and deep 
group of muscles of the posterior compartment and the muscle belly of gastrocnemius 
can be easily separated from the deep flexor compartment by either sharp or blunt 
dissection. The flexor compartment lies in close proximity to the tibia proximally and 
distally to the united tibia and fibula. In the distal one-third of the leg the Achilles 
tendon is separated from the tibia and the flexor tendons by a constant presence of 
loose areolar tissue.  Neurovascular bundles are seen to run in the loose areolar tissue 
close to the anterior aspect of the Achilles tendon. The tendon is inserted into the 
posterior aspect of the calcaneum. It is surrounded by a layer of paratenon which can 
be dissected away. The tendon is round in cross section at its waist but flattens out at 
insertion. 
 
The tendon is subcutaneous and is easily accessible through a midline incision at the 
back of the leg. The plantaris tendon is separated from the body of the Achilles tendon 
by gentle dissection so as to prevent bleeding from the fragile vessels in the paratenon 
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particularly near the ankle region. The plantaris is retracted to one side and the tendon 
is ready for manipulation.  
 
 
 
 
     
 
 
 
 
 
 
 
 
 
Figure 3.1 - Macroscopic anatomy of Achilles tendon by cadaveric dissection- a) and b) Fascial plane 
between superficial and deep compartment, c) and d) Formation of Achilles tendon with blood vessels 
lying anterior to the tendon 
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Figure 3.2 -Transverse  serial  section through Decalcified mouse leg from Proximal to Distal (Top to 
Bottom) – 2mm segments, image captured from above and below the cuts, AT-Achilles tendon, S0-
Soleus, GC- gastrocnemius. Scale Bar- 1 mm 
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The Achilles tendon is covered by a thin layer of fascial covering which is commonly 
termed the paratenon. Fascial extensions are seen passing from the skin to the 
paratenon. The paratenon is continuous anteriorly with a fascial sleeve, commonly 
termed the mesotenon where blood vessels could be visualised with the naked eye. 
Individual components of the tendon (soleus and gastrocnemius) can be stripped 
separately as they each have their own fascial sheath. 
 
 
 
Figure 3.3 - Fascial extensions of the Achilles tendon sheath showing gradual separation of the skin from the tendon 
(i) and (ii)  and thin fascial extensions(iii) (Black arrow) passing from the skin into the tendon sheath /paratenon 
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3.1.2 Microscopic anatomy  
 
Transverse and longitudinal sections of the decalcified leg showed the relationship of 
Achilles tendon to other structures in the leg. The tendon is seen to be formed  by the 
union of two separate tendons of soleus and gastrocnemius (Figure  3.4 and Figure 3.5). 
It flattens out to insert into the calcaneum. The thin plantaris tendon is seen passing 
into the foot and continuing into the plantar fascia. Three dimensional reconstruction of 
the mouse leg was done using H&E stained serial sections. The reconstruction shows 
the relationship of the Achilles tendon to its surrounding structures (Figure 3.4). 
 
 Hoechst and TRIT-C Phalloidin stain demonstrated the parallel distribution of cells 
along the long axis of the tendon (Figure 3.6). Alcian blue staining did not reveal any 
areas of fibrocartilage in the main body of the tendon but   showed increased blue hue 
and rounded cells at the enthesis region adjacent to calcaneal insertion (Figure 3.7). 
There was also an increase in proteoglycan content at the region where soleus and 
gastrocnemius tendons join to form the Achilles Tendon(Figure 3.9).  The collagenous 
and elastic component of Achilles tendon was demonstrated by Masson’s Trichrome 
stain (Figure 3.10) and Miller’s Elastin stain resepectively (Figure 3.11). 
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Figure 3.4 -Three dimensional reconstruction of the posterior compartment of mouse leg using H&E 
stained serial section showing relative relationship of structures. Scale Bar 1mm 
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Figure 3.5 - Histological study of Achilles tendon in serial cross section from proximal to distal (stained 
with H&E) showing formation, rotation and insertion of the tendon  
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Figure 3.6 - (a) and (b) Longitudinal Section of filleted Achilles tendon , (a) H&E stain ; (b) Hoechst and 
TRITC Phalloidin  stain showing Cellular arrangement in parallel rows and.   Magnification x5; ScaleBar- 
500 µm 
 (c-e) Cross section of the Achilles tendon showing intercellular cytoplasmic projections,(c)  H&E and(d) 
and (e)  Hoechst and TRITC Phalloidin stain on the right, (c) and (d)   Magnification x5 ; Scale Bar-200 µm, 
(e) Magnification x10;  scale bar- 50 µm 
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Alcian blue staining showed that the fascial envelope is high in proteoglycans and has a 
loose areolar distribution (Figure 3.8). An increase in proetoglycans at the region of 
union of soleus and gastrocnemius was seen and this could be demonstrated both in 
longitudinal and cross sections of the tendon. The tendon proper shows no obvious 
areas of fibrocartilaginous zones. Cellular morphology changed from oval to rhomboid 
as the tendon approached the bony insertion (Figure 3.7).  
 
 
 
Figure 3.7- Longitudinal Section of the enthesis region showing change in cell morphology from 
elongated to rounded with cells of fibrocartilage staining blue x10 (Alcian blue stain), Fibrocartilage  
shown with Black Arrow, Magnification x 10 ;  Scale Bar-500µm 
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Figure 3.8 - The gliding fascia around Achilles tendon. Black arrow in (a) denotes fascial layer between 
Achilles tendon and plantaris.  (b) Black arrow indicates space between Achilles tendon and paratenon 
and Red arrow indicates paratenon, Magnification -x5 - alcian blue stain 
 
 
 
 
 
                                                    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 - Alcian blue staining showing increase bluish hue where the soleus and the gastrocnemius 
tendons join together to form the Achilles tendon (Black arrow). This is demonstrated both in 
longitudinal (a and b) and cross sections (c) of the Achilles tendon Magnification x 5; Scale Bar- 500 µm 
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Figure 3.10- Serial longitudinal sections of mouse leg stained with Masson’s Trichrome stain showing 
collagenous content of Achilles tendon.  Magnification x 5, Scale Bar- 1 mm 
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Figure 3.11- Serial sagittal section of the mouse leg (Decalcified sections) stained with Miller’s elastin 
showing the highly elastic nature of the Achilles tendon. Magnification x 5;  Scale Bar- 1mmm 
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3.1.3 Study of vascular architecture with Alpha-SMA immunostaining 
 
Alpha SMA staining showed that the tendon substance was avascular (Figure 3.12 - 
3.14). In transverse sections   abundant blood vessels were seen in the loose areolar 
tissue anterior to the tendon. The mesotenon appears to bring the blood vessels to the 
tendon as demonstrated by serial cross section immunohistochemistry (Figure 3.14). At 
the musculotendinous junction blood vessels were seen in the connective tissue 
between soleus and gastrocnemius muscle/tendon. Two sets of vessels were seen on 
either side of the tendon but only one of these appears to be contributing to the 
vessels supplying the tendon through the mesotenon (Figure 3.14). Nonlumen related 
Alpha-SMA staining was found in the epitenon areas of the Achilles tendon (Figure 
3.13b). 
 
 
Figure 3.12 - Longitudinal section of the leg showing large calibre lumen related Alpha-SMA stain in the 
paratenon  proximal to the tendon proper likely to represent the Posterior Tibial vessels Magnification x5 
;  Scale Bar 200 µm 
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Figure 3.13- Longitudinal section of the Achilles tendon with Alpha SMA Stain showing (b) non-lumen 
related Alpha- SMA positive cells (Myofibroblasts) in the epitenon and (c) lumen related Alpha- SMA 
positive cells in the paratenon and skin and; (a) Scale Bar- 500 µm (b) and (c) Scale bar-50 µm 
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Figure 3.14- Serial transverse section, top left proximal to bottom right distal, of the Mouse Achilles 
tendon (Filleted off the bone) showing blood vessels present in the loose areolar tissue- anterior(Orange 
arrow) and lateral (Green arrow)to the Achilles tendon and in the dermis of the skin (Blue arrow). Small 
blood vessels are also seen in the epitenon and endotenon (red arrow). GC- Gastrocnemius, So-Soleus. 
Distance between sections shown are 70 um, captured at x5; Scale Bar-500 µm 
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3.2 Results of tendon grafting studies  
 
3.2.1 Summary  
 
At   Day 3   the transgenic tendon graft was intact (GFP staining) and was separated 
from the main tendon by a fibrin clot. No obvious sign of necrosis was seen. No cellular 
invasion was apparent. The sheath was hypercellular with predominantly neutrophils 
(Ly6G staining) and macrophages (F4/80 staining). The recipient tendons also appeared 
intact showing no cellular invasion from the sheath. 
 
At Day 21 the GFP positive graft continued to express GFP and both graft tendon cells 
and host tendon cells show marked collagen synthetic activity (Hsp47). By this time 
sheath hypercellularity had reduced. Staining with apoptotic marker (Tunel) showed a 
number of apoptotic cells both in the graft and in the host tendon. 
 
At Day 90 the grafts appeared almost completely integrated to host tissue and GFP 
positive cells were no longer present in the GFP graft. There was a moderate amount of 
collagen synthetic activity in the tendon and sheath and a number of cells continued to 
show signs of apoptosis. 
 
Autologous grafts showed similar cellular events with a slightly lower neutrophilic 
response. Control unwounded tendons showed almost no synthetic or apoptotic 
activity at any point. 
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3.2.2 Staining for inflammatory cells- CD45, Ly6G and F4/80 
 
The pattern of the cellular changes following grafting was similar between autografts 
and syngenic grafts however the amount of cellular activity did differ between certain 
aspects of the healing process. The pattern of inflammation following grafting showed 
an intense inflammatory reaction in the subcutaneous tissue at Day 3, followed by an 
increase in inflammatory cells in the host tendon and grafted tendon at Day 21, which 
gradually diminished but never quite reached baseline levels in all tissues at Day 90 
(Figure 3.15).  The initial inflammatory response (Day 3) as measured by CD45 and Ly6G 
was greater in syngenic grafting subcutaneous tissue when compared with the 
subcutaneous tissue of autografts (CD45 2075 ±181 vs. 1211 ±81 cells/mm2 and Ly6G 1587 
±65 vs. 1050 ±52 cells/mm2) (Figure 3.15-  Figure 3.22). However F480 expression was 
greater in autograft subcutaneous tissue when compared with syngenic subcutaneous 
tissue (autogenous 1355 ±50 vs. syngenic 1044 ±30 cells/mm2) at Day 3 (Figure 3.23-
Figure 3.26). These findings were shown to be statistically significant (p < 0.001).  
 
Figure 3.15 - Graphical representation of inflammatory cells in the graft, host tendon and in the 
subcutaneous tissue at Day 3, Day 21 and Day 90.  Inflammation in the tendon lags behind subcutaneous 
tissue and only reaches similar activity at Day 21. 
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3.2.2.1 CD45 Staining 
 
Tendon grafting invoked a marked inflammatory response in the subcutaneous tissue 
surrounding the grafted tendon with a large number of CD45 positive cells found 
homogeneously distributed in dermis, epidermis and paratenon (1211± 81 in autograft 
and 2075 ± 181 in syngenic graft). The number of CD45 positive cells in the subcutaneous 
tissue reduced significantly by Day 21 and only a very small number of these cells were 
present at Day 90. At Day 3, there were insignificant numbers of CD45 positive cells in 
both the donor and the host tendons. The small number of cells present in the tendon 
was found in the epitenon and around the sutures. By Day 21 the core of the tendon 
graft was invaded by a large number of CD45 positive cells (445 ± 53 in autograft and 
757 ± 118 in syngenic graft).  The host tendon remained unaffected and only a few cells 
were found inside it (199 ± 21 in autograft and 238 ± 58 in syngenic graft). At Day 90, the 
inflammatory influxes were reduced from all areas of the leg but a small number 
remained in the graft and the paratenon (Table 3.1). 
 
Table 3.1- CD45 Stain- Number of cells/mm2 and corresponding SEM (n=4 mice/time 
point, 3 slides/mice) 
 
CD45 Control Day 3 Day 21 Day 90 Control 
SEM 
Day 3 
SEM 
Day 21 
SEM 
Day 90 
SEM 
Syngenic 
Tendon Graft 
0 83.32 757.81 406.25 0 21.35 118.31 53.90 
Syngenic 
Host Tendon 
21.87 36.40 238.28 180.98 7.95 9.48 58.28 34.68 
Syngenic 
Subcutaneous 
tissue 
206.25 2075 489.53 496.09 42.33 181.87 40.78 79.06 
Autograft 
Tendon Graft 
0 45.45 445.31 281.25 0 13.71 53.06 47.21 
Autograft 
Host Tendon 
21.87 62.5 199.21 209.63 7.96 14.73 21.93 29.93 
Autograft 
Subcutaneous 
tissue 
206.25 1211.56 407.55 253.90 42.32 81.06 44.5 27.53 
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Figure 3.16 -Graphical Representation of the Chronological events after syngenic and autologous Tendon 
grafting- CD45 Stain for panleukocytes. The initial inflammatory response (Day 3) as measured by CD45 
was greater in syngenic grafting subcutaneous tissue when compared with the subcutaneous tissue of 
autografts (CD45 2075 ±181 vs 1211 ±81 cells/mm2). Significance recorded with * in the graph if p-value was   
less than 0.05 and   **  if  p was less than 0.001. 
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Figure 3.17 - Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 3 showing staining for 
leukocytes with CD45 Magnification x5; Bar-500 µm.  (b) and (c) Subcutaneous tissue in both grafts show 
massive influx of CD45 positive cells; Magnification x 10; Bar-100 µm 
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Figure 3.18- Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 21 showing staining for 
leukocytes with CD45. Magnification x5; Bar-500 µm Subcutaneous tissue in both grafts show infiltration 
of  Cd45 positive cells inside the tendon graft in (b) Syngenic and (c) Autologus grafts; Magnification x10; 
Bar-100 µm  
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Figure 3.19 - Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 90 showing staining for 
leukocytes with CD45. Magnification x5; Bar-500 µm Subcutaneous tissue in both grafts show very few 
Cd45 positive cells; Only a small number of Cd45 cells remained in the(b)  syngenic and (c) autologous 
tendon; Magnification x10; Bar-100 µm 
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3.2.2.2 Ly6G Staining 
 
At Day 3, many of the cells in the subcutaneous tissue were positive for Ly6G, indicating 
a significant neutrophilic infiltration (1050 ± 52 in autograft and 1587 ± 64 in syngenic 
graft) . The number of Ly6 positive cells in the subcutaneous tissue reduced significantly 
by Day 21 and  remained  at a  similar  level of activity at Day 90. 
 
At   Day 3, there were very few Ly6G positive cells in both the donor and the host 
tendon. The majority of the inflammatory cells were seen at the periphery of the 
tendons near the epitenon.  By Day 21, the core of the tendon graft had a significantly 
large number of Ly6G positive cells (433 ± 37  in autograft and 725 ± 70).  The host 
tendons were not invaded by   the neutrophils at any time point and only a few cells 
were found inside it from Day 3 to Day 90 (Table 3.2). 
  
Table 3.2- Ly6G Stain- Number of cells/mm2 and corresponding SEM (n=4, 3 slides/mice) 
 
Ly6G Control Day 3 Day 21 Day 90 Control 
SEM 
Day 3 
SEM 
Day 21 
SEM 
Day 90 
SEM 
Syngenic 
Tendon Graft 
0.00 110.68 725.16 136.72 0.00 29.56 70.47 23.72 
Syngenic 
Host Tendon 
15.63 35.16 109.38 28.59 4.94 18.55 26.41 10.68 
Syngenic 
Subcutaneous 
tissue 
131.25 1587.19 489.53 153.64 25.48 64.80 31.74 27.26 
Autograft 
Tendon Graft 
0.00 39.06 433.59 225.16 0.00 8.92 37.19 35.47 
Autograft 
Host Tendon 
15.63 27.34 285.16 208.28 4.94 8.63 39.69 21.78 
Autograft 
Subcutaneous 
tissue 
131.25 1050.78 486.97 404.84 25.47 52.14 27.11 35.16 
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Figure 3.20- Graphical representations of chronological events after syngenic and autologus grafting  
with Ly6G stain. The initial inflammatory response (Day 3) as measured by Ly6G was greater in syngenic 
grafting subcutaneous tissue when compared with the subcutaneous tissue of autografts (1587 ±65 vs 
1050 ±52 cells/mm2). Significance   recorded with * in the graph if p-value was   less than 0.05 and   **  if  p 
was less than 0.001. 
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Figure 3.21 -Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 3 showing staining for 
neutrophils with Ly6G. Magnification x5; Bar-500 µm Subcutaneous tissue show large number of Ly6G 
positive cells in both (b)  syngenic and (c) autologous tendon; Magnification x10; Bar-100 µm  
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Figure 3.22 - Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 21 showing staining for 
neutrophils with Ly6G. Magnification x5; Bar-500 µm. Grafts show infiltration with Ly6G  positive cells 
both in the(b)  syngenic and (c) autologous tendon; Magnification x10; Bar-100 µm 
 
 
 
 
104 
 
 
 
Figure  3.23 -Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 90 showing staining for 
neutrophils with Ly6G. Magnification x5; Bar-500 µm Subcutaneous tissue in both grafts show very few 
Ly6G positive cells; Only a small number of Ly6G positive cells remained in the(b)  syngenic and (c) 
autologous tendon; Magnification x10; Bar-100 µm 
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3.2.2.3 F4/80 Staining 
 
At day 3, the subcutaneous tissue was hyper cellular and the presence of large numbers 
of F4/80 positive cells was indicative of   accumulation of macrophages in this area (1355 
± 50 in autograft and 1044 ± 29 in syngenic graft). The number of F4/80 positive cells in 
the subcutaneous tissue reduced gradually by Day 21 and remained higher than normal 
at day 90.  
  
At Day 3, there were very few F4/80 positive cells in both the donor and the host 
tendon. By Day 21 the core of the tendon graft was highly cellular with whirling patterns 
of cells, many of which were positive forF4/80 (385 ± 42 in autograft and 445 ± 40 in 
syngenic graft).  The host tendon also showed a small rise in the numbers of 
macrophages at Day 21.  At Day 90, macrophages had reduced from all areas of the leg 
but a small number remained in the graft and the paratenon (Table 3.3). 
 
Table 3.3- F4/80 Stain- Number of cells/mm2 and corresponding SEM (n=4 mice/time 
point, 3 slides/mice) 
 
F480 Control Day 3 Day 21 Day 90 Control 
SEM 
Day 3 
SEM 
Day 21 
SEM 
Day 90 
SEM 
Syngenic 
Tendon Graft 
0.00 57.30 445.31 143.13 0.00 15.30 40.22 23.69 
Syngenic 
Host Tendon 
28.13 31.25 190.10 52.08 14.31 12.16 44.38 14.81 
Syngenic 
Subcutaneous 
tissue 
193.75 1044.22 523.44 207.03 13.62 29.97 62.66 29.53 
Autograft 
Tendon Graft 
0.00 67.70 385.41 342.44 0.00 12.36 42.89 63.83 
Autograft 
Host Tendon 
28.13 55.94 231.72 196.61 14.32 14.19 26.25 27.09 
Autograft 
Subcutaneous 
tissue 
193.75 1355.47 395.78 265.63 13.62 50.00 45.47 30.64 
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Figure 3.24 - Graphical representations of chronological events after syngenic and autologus grafting 
with F4/80 stain. Significance   recorded with * in the graph if p-value was   less than 0.05 and   **  if  p 
was less than 0.001. 
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Figure 3.25- Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 3 showing staining for 
Macrophages with antibody against F4/80. Magnification x5; Bar-500 µm Subcutaneous tissue in both 
grafts shows huge influx of macrophages in the subcutaneous tissue both in the (b) Syngenic and (c) 
Autologous grafts; Magnification x10; Bar-100 µm 
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 Figure 3.26 - Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 21  showing staining for 
macrophages with antibody against F4/80. Magnification x5;  Bar-500 µm. Both grafts shows infiltration 
of  F4/80 positive cells inside the tendon graft in (b) Syngenic and (c) Autologous grafts; Magnification 
x10; Bar-100 µm
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Figure 3.27- Sagittal section of (a) Syngenic and (d) Autologous grafting at Day 90  showing staining for 
macrophages with F4/80. Magnification x5; Bar-500 µm. Small number of macrophages remain in the 
tendon of both (b) Syngenic and (c) Autologous grafts; Magnification x10; Bar-100 µm
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 3.2.3 Cellular repopulation- GFP Immunisation 
 
When   GFP tendon was grafted onto a C57 host, the number of GFP increased per unit 
area due to the GFP labelled cells coalescing (Figure 3.28c and Figure 3.29 a-e). However 
GFP expression rapidly disappeared by Day 90. At day 3 the cellular architecture of the 
graft appeared normal and cell nuclei were oval in shape and distributed parallel to the 
long axis of the tendon. At Day 21, the oval GFP positive tendon cells were surrounded 
by a huge number of round cells many of which stained positive for CD45 and F4/80 
confirming the inflammatory nature of the infiltrate. Though the tendon cells retained 
their shape, their longitudinal orientation was lost and a whirling   pattern was seen. 
The graft tendon was enveloped in a rim of inflammatory cells which indicated the 
previous margin of the graft. The actual outline of the graft at day 21 was indistinct. The 
placement of the suture, the rim of inflammatory tissue, the pattern of distribution of 
cells and the presence or absence of GFP stains all contributed to the identification of 
the outline of the graft.  At day 90, a few isolated GFP positive cells were present in the 
area of the graft. 
 
When a graft harvested from C57 mice was placed in the GFP host (Figure 3.28a) or a 
GFP graft in the GFP mouse was done (Figure 3.28b), at day 3 the GFP stain showed GFP 
positive cells in the subcutaneous tissue and host tendon and only a small number of 
GFP positive cells in the non GFP graft. These GFP positive cells were rounded and most 
likely inflammatory in origin. At day 21, the C57 graft had many GFP positive non tendon 
cells in the core.  At day 90, the outline of the graft could only be demarcated if sutures 
were viewed. 
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Table 3.4- GFP Stain- Number of cells/mm2 and corresponding SEM (n=4 mice/time 
point, 3 slides/mice) 
 
 
 
Control Day 3 Day 21 Day 90 Control SEM Day 3 SEM Day 21 SEM Day 90 SEM 
C57 graft on 
GFP  mouse 
        
C57 Tendon 
Graft 
0.00 23.44 593.75 372.39 0.00 10.47 67.02 99.69 
GFP Host 
Tendon 
387.50 466.09 356.77 263.02 29.38 64.84 42.95 77.53 
GFP Host 
Subcutaneous 
tissue 
584.38 1653.59 575.47 520.78 37.17 252.66 101.41 110.16 
GFP graft on 
C57  mouse 
        
GFP Tendon 
Graft 
0.00 963.55 1283.75 111.98 0.00 158.19 203.58 37.92 
C57 Host 
Tendon 
0.00 13.02 18.23 0.00 29.39 13.02 18.23 0.00 
C57 Host 
Subcutaneous 
tissue 
0.00 7.81 65.09 7.81 0.00 7.81 42.66 7.81 
GFP graft on 
GFP mouse 
        
GFP 
Autograft 
Tendon Graft 
0.00 359.38 593.75 559.84 0.00 39.52 67.02 83.69 
GFP 
Autograft 
Host Tendon 
387.50 401.04 356.72 489.58 29.38 55.47 42.95 55.55 
GFP 
Autograft 
Subcutaneous 
tissue 
584.38 1596.35 575.47 604.17 37.17 252.19 101.41 49.84 
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Figure 3.28- Graphical representation of chronological events after syngenic and autologous grafting with 
GFP stain. In both( A)- C57 graft on GFP mouse and (B)- GFP autograft in GFP mouse-  GFP staining peaked 
in the subcutaneous tissue at Day 3 due the large inflammatory influx and in (C) GFP graft in C57 mouse- 
GFP staining in the graft peaked at Day 21 due to crowding of the graft cells and disappeared by Day 90. 
Significance   recorded with * in the graph if p-value was   less than 0.05 and   **   if p   was less than 
0.001. 
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Figure 3.29 -  Fate of grafted cells with GFP stain after grafting of GFP positive graft into C57 mice 
showing results at (a)  Day 3, (b) Day 21,  and (c) Day 90 . Graft is outlined in black. Arrows indicate 
securing sutures. Magnification x5, Bar- 500 µm. (d) Day 3 and (e) Day 21 GFP stained cells showing 
increaseed cell density of cells at Day 21
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3.2.4 Cellular proliferation- BrdU immunostaining 
 
The pattern of cellular proliferation showed a gradual increase in BrdU staining from 
control levels after grafting that mainly occurred in the subcutaneous tissues, whereas 
BrdU expression peaked in the host tendon and the tendon graft at Day 21 and 
gradually diminished at Day 90 (Figure 3.30- Figure 3.33). BrdU expression at Day 21 was 
significantly greater in the subcutaneous tissue in the syngenic model compared with 
the autograft (1275 ±117 vs. 843 ±139 cells/ mm2) and greater in the syngenic tendon 
graft when compared to autograft at Day 90 ( 523±117 vs. 244±37 cells/mm2) (p <0.05) 
(Table 3.5). 
 
Table 3.5- BrdU Stain- Number of cells/mm2 and corresponding SEM (n=4 mice/time 
point, 3 slides/mice) 
 
BrdU Control Day 3 Day 21 Day 90 Control 
SEM 
Day 3 
SEM 
Day 21 
SEM 
Day 90 
SEM 
Syngenic 
Tendon Graft 
0.00 57.29 632.81 523.44 0.00 19.21 88.59 117.03 
Syngenic 
Host Tendon 
84.38 28.64 393.23 286.45 15.30 13.02 22.61 52.34 
Syngenic 
Subcutaneous 
tissue 
425.00 734.38 1275.94 1166.56 34.02 100.47 117.97 105.94 
Autograft 
Tendon Graft 
0.00 92.44 584.63 244.69 0.00 22.81 111.17 37.48 
Autograft 
Host Tendon 
84.38 32.55 406.25 234.38 15.31 7.78 91.98 13.94 
Autograft 
Subcutaneous 
tissue 
425.00 760.42 843.75 1010.31 34.02 18.59 139.06 87.34 
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 Figure 3.30 -Graphical representation of BrdU positive cells in syngenic and autografts at Day 3, Day 21 
and Day 90. Activity in subcutaneous tissue remains much greater than tendon tissue at all time points. 
BrdU expression at Day 21 was significantly greater in the subcutaneous tissue in the syngenic model 
compared with the autograft (1275 ±117 vs 843 ±139 cells/ mm2) and greater in the syngenic tendon graft 
when compared to autograft at Day 90( 523±117 vs 244±37 cells/mm2) (p <0.05). Significance   recorded 
with * in the graph if p-value was   less than 0.05 and   **  if  p was less than 0.001. 
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Figure 3.31- (a) Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing BrdU staining at Day 3.  Graft outlined with black line, small arrows indicating the sutures used 
to secure the graft; Magnification x5, Bar-500 µm (b) The subcutaneous tissue has a large number of 
BrdU positive cells while (c) graft tendon shows only a small number of BrdU positive cells in the 
periphery, Magnification x20, Bar-100 µm 
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Figure 3.32- (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  BrdU staining at Day 21.  Graft outlined with black line, small arrows indicating the sutures used 
to secure the graft; Magnification x5, Bar-500 µm.(b) The subcutaneous tissue still  has a large number of 
BrdU positive cells while (c) graft tendon shows an increase in the number of BrdU positive cell;, 
Magnification x20, Bar-100 µm
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Figure 3.33 - (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  BrdU staining at Day 90.  Graft outlined with black line, small arrows indicating the sutures used 
to secure the graft; Magnification x5, Bar-500 µm. Proliferative activity remains higher than normal in (b) 
Graft  and host tendon and (c) Subcutaneous tissue, Magnification x20, Bar-100 µm 
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3.2.5 Collagen synthesis- Hsp47 Immunostain 
Collagen synthesis as measured by Hsp 47 expression was increased in the 
subcutaneous tissues initially at 3 days followed by increased expression in the host 
tendon and tendon graft at Day 21, reducing to baseline levels at Day 90 (Figure 3.34- 
Figure 3.37).  
 
Hsp 47 expression was significantly greater in the autografted subcutaneous tissue at 
Day 3 and Day 90 when compared with syngenic subcutaneous tissue, however 
syngenic tendon grafts showed marked significantly greater Hsp 47 expression at Day 
21 when compared to tendon autograft (1182±80 vs 839 ±77 cells/ mm2).  
 
At Day 3 Hsp47 positive cells were seen in small numbers in all parts of the leg but there 
were significantly more cells in the subcutaneous areas than in the tendon tissue. The 
subcutaneous tissue maintained a similar level of activity at Day 21 but at day 90 this had 
reduced to a much lower level. At Day 21 the area of the graft showed a massive 
increase in Hsp47 activity which was obvious in all samples at this time point (Table 3.6).  
 
The host tendon also participated in collagen synthesis and this was more prominent in 
the areas surrounding the donor graft (Figure 3.36). Though collagen synthesis reduced 
in all parts of the sample by day 90, the area of the graft continued to show a higher 
activity than the rest of the tendon. Cell alignment was restored to normal longitudinal 
orientation (Figure 3.37). 
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Table 3.6- Hsp47 Stain- Number of cells/mm2 and corresponding SEM (n=4 mice/time 
point, 3 slides/mice) 
 
 
Hsp47 Control Day 3 Day 21 Day 90 Control 
SEM 
Day 3 
SEM 
Day 21 
SEM 
Day 90 
SEM 
Syngenic 
Tendon Graft 
0.00 232.97 1182.19 337.24 0.00 23.03 80.02 66.98 
Syngenic 
Host Tendon 
59.38 236.98 457.03 139.22 13.44 32.11 65.89 34.38 
Syngenic 
Subcutaneous 
tissue 
181.25 648.44 667.97 291.66 29.06 52.92 51.64 47.19 
Autograft 
Tendon Graft 
0.00 347.66 839.84 312.50 0.00 40.00 77.81 27.97 
Autograft 
Host Tendon 
59.38 286.41 524.69 179.69 13.44 33.91 54.20 20.66 
Autograft 
Subcutaneous 
tissue 
181.25 830.72 505.16 539.06 29.06 38.59 48.59 53.28 
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Figure 3.34- Graphical representation of chronological events after syngenic (above) and autologous 
(Below) grafting with Hsp47 stain. Hsp 47 expression was significantly greater in the autografted 
subcutaneous tissue at Day 3 and Day 90 when compared with syngenic subcutaneous tissue, however 
syngenic tendon grafts showed marked significantly greater Hsp 47 expression at Day 21 when compared 
to tendon autograft (1182±80 vs 839 ±77 cells/ mm2). Significance   recorded with * in the graph if p-value 
was   less than 0.05 and   **  if  p was less than 0.001. 
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Figure 3.35 - (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  Hsp47 staining at Day 3  showing collagen synthesis.  Graft outlined with black line, small arrows 
indicating the sutures used to secure the graft; Magnification x5, Bar-500 µm.(b) The subcutaneous tissue 
showing significant increase in collagen synthesis (DAB staining-Black) while (c) Graft tendon shows a 
moderate level of activity;, Magnification x20, Bar-100 µm
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Figure 3.36 - (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing intense HSP47 staining in all areas  at Day 21. Graft outlined with black line, small arrows 
indicating the sutures used to secure the graft; Magnification x5, Bar-500 µm. (b) The subcutaneous 
tissue continues to show high levels of collagen synthesis (DAB staining-Black) while (c) Graft tendon 
shows a marked rise in synthetic activity; Magnification x20, Bar-100 µm
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Figure 3.37- (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  Hsp47 staining  at Day 90. Graft outlined with black line, small arrows indicating the sutures 
used to secure the graft; Magnification x5, Bar-500 µm. (b) Only a small number of cells in  subcutaneous 
tissue and (c) Graft tendon show synthetic activity; Magnification x 20, Bar-100 µm
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3.2.6 Cellular  Apoptosis- TUNEL  Immunostain 
 
Apoptosis as measured by TUNEL expression showed a gradual increase from Day 3 
reaching a peak at Day 21 and diminishing by Day 90(Figure 3.38- Figure 4.41). Syngenic 
grafts showed a far greater expression of TUNEL at Day 21 than autograft tendon (1109± 
122 vs. 626 ±81 cells/mm2) which was significant (p < 0.001). 
 
At Day 3 TUNEL positive apoptotic cells were seen in small numbers in all parts of the 
leg but there were significantly more cells in the subcutaneous areas than in the tendon 
tissue (Figure 3.39).  The subcutaneous tissue maintained a similar level of activity at 
Day 21 through to   Day 90. At day 21 many of the cells in the area of the graft stained 
positive for TUNEL (Figure 3.40). By day 90 apoptosis has reduced to a very low level in 
all parts of the host and graft tendon (Figure 3.41). The donor tendon maintained a low 
level of apoptosis at all time points (Table 3.7). 
 
Table 3.7- TUNEL Stain- Number of cells/mm2 and corresponding SEM (n=4 mice/time 
point, 3 slides/mice) 
 
TUNEL Control Day 3 Day 21 Day 90 Control 
SEM 
Day 3 
SEM 
Day 21 
SEM 
Day 90 
SEM 
Syngenic 
Tendon Graft 
0.00 82.03 1109.38 126.41 0.00 10.38 122.80 21.42 
Syngenic 
Host Tendon 
106.25 48.17 175.78 106.53 11.47 19.66 46.72 20.41 
Syngenic 
Subcutaneous 
tissue 
337.50 516.88 688.75 570.94 37.17 53.72 75.94 66.80 
Autograft 
Tendon Graft 
0.00 147.03 626.25 199.22 0.00 23.11 81.25 44.66 
Autograft 
Host Tendon 
106.25 92.44 438.75 121.09 11.47 14.45 68.78 29.23 
Autograft 
Subcutaneous 
tissue 
337.50 524.69 658.85 451.72 37.17 64.38 73.42 47.81 
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Figure 3.38 – Graphical representation of chronological events after syngenic (top) and autologous 
(bottom) grafting with TUNEL stain showing apoptosis. TUNEL expression showed a gradual increase 
from control non injured tissues at Day 3 reaching a peak at Day 21 and diminishing by Day 90. Syngenic 
grafts showed a far greater expression of TUNEL at Day 21 than autografted tendon (1109± 122 vs 626 ±81 
cells/mm2) which was significant (p < 0.001).Significance   recorded with * in the graph if p-value was   
less than 0.05 and   **  if  p was less than 0.001. 
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Figure 3.39- (a) Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing TUNEL staining at Day 3.  Graft outlined with black line, small arrows indicating the sutures used 
to secure the graft; Magnification x5, Bar-500 µm.(b) The subcutaneous tissue  has a large number of 
TUNEL  positive cells  while (c) Graft tendon shows only a small number of TUNEL  positive cells, 
Magnification x20, Bar-100 µm 
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Figure 3.40- (a) Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  TUNEL staining at Day 21.  Graft outlined with black line, small arrows indicating the sutures 
used to secure the graft; Magnification x5, Bar-500 µm. (b) The subcutaneous tissue still has a large 
number of TUNEL positive cells while (c) Graft tendon shows a significant rise in the number of apoptotic 
cells, Magnification x20, Bar-100 µm
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Figure 3.41- (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  TUNEL staining at Day 90.  Graft outlined with black line, small arrows indicating the sutures 
used to secure the graft; Magnification x5, Bar-500 µm. (b) The subcutaneous tissue and (c) Graft tendon 
shows a small number of apoptotic cells, Magnification x20, Bar-100 µm 
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3.2.7 Staining for vascular pericytes-Alpha SMA Immunostaining 
 
 Alpha SMA staining highlighted two types of structures- one was associated with 
lumens and the other was non lumen related individual cellular stains. Lumen related 
Alpha- SMA staining showed a significant (p < 0.05) increase in the vascularity of the 
subcutaneous tissue at Day 3 (74.21± 7.72 and 53.38±6.7 cells/mm2   in syngenic and 
autografts respectively), compared to control unwounded tendons (21.875± 13.6 
cells/mm2  ). Vascularity   remained at high levels at Day 21 (66.4±9.04 in syngenic and 
55.98± 5.25 cells/mm2   in autografts) and at Day 90 (67.7±5.87in syngenic and 37.7± 7.05 
cells/mm2   in autografts) (Figure 3.42- Figure 3.45). Vessel related Alpha SMA staining 
was absent   in the control unwounded tendons and in the   tendon substances at Day 3 
.Blood vessels were seen in the tendon graft at Day 21 (29.94±11.6 and 14.32±4.88 
cells/mm2   in syngenic grafts and autografts) which reduced in number by Day 90 
(1.3±1.3 and 6.51±3.57 cells/mm2  in syngenic grafts and autografts). A very small number 
of blood vessels were also seen in the host tendon at day 21 (7.816±3.59 and 7.81±4.5 
cells/mm2 in syngenic grafts and autografts. Non lumen related Alpha SMA staining was 
present in the subcutaneous tissue at all time points and in the tendon graft at Day 21 
and Day 90. 
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Figure 3.42 - Graphical representation of chronological events after syngenic (top) and autologous 
(bottom) grafting with Alpha-SMA staining showing vascularisation. Alpha- SMA staining showed a 
significant (p < 0.05) increase in the vascularity of the subcutaneous tissue at Day 3 ( 74.21± 7.72 and 
53.38±6.7 cells/mm2  in syngenic  and autografts respectively) , compared to control unwounded tendons 
( 21.875± 13.6 cells/mm2  ). Significance   recorded with * in the graph if p-value was   less than 0.05 and   
**  if  p was less than 0.001. 
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Figure 3.43 - (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  Alpha SMA Day 3.  Graft outlined with black line, small arrows indicating the sutures used to 
secure the graft; Magnification x5, Bar-500 µm.(b) The subcutaneous tissue  has a large number of lumen 
related Alpha-SMA  positive cells  indicating  angiogenesis associated with inflammatory phase of healing 
while (c) Graft tendon shows no  lumen related Alpha SMA  staining, Magnification x20, Bar-100 µm 
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Figure 3.44- (a)  Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  Alpha SMA at Day 21.  Graft outlined with black line, small arrows indicating the sutures used to 
secure the graft; Magnification x5, Bar-500 µm.(b) The subcutaneous tissue  still shows  a large number of 
lumen related Alpha-SMA  positive cells  c) Graft tendon also shows appearance of a number of lumen 
related Alpha SMA  staining, Magnification x20, Bar-100 µm 
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Figure 3.45 - (a) Sagittal section of the Achilles tendon and surrounding skin and subcutaneous tissue 
showing  Alpha SMA at Day 90.  Graft outlined with black line, small arrows indicating the sutures used to 
secure the graft; Magnification x5, Bar-500 µm.(b) The subcutaneous tissue  continues to  show  a 
number of lumen related Alpha-SMA  positive cells  c) Graft tendon also shows a small number of lumen 
related Alpha SMA  staining, Magnification x20, Bar-100 µm 
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3.2.8 Three dimensional cell mapping 
 
In order to achieve a better spatiotemporal orientation of cellular activity three 
dimensional reconstruction were done from serial section immunohistochemistry 
(Figure 3.46- 3.48). which showed overlapping of GFP positive cells and HSp47 positive 
cells  further  proving that graft cells actively synthesize collagen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.46- Building of three dimensional reconstructions from serial section immunohistochemistry, 
First the areas are outlined and marled out with a chosen colour. In this case subcutaneous tissue is 
marked grey, graft-green and host tendon –red. Stained cells are then plotted into the image 
 
136 
 
3.2.8.1 Inflammatory profile 
 
Three Dimensional Reconstruction of serial sections (Figure 3. 47 a-c) showed that at 
Day 3 (Figure 3.47a) inflammatory cells (outlined with yellow dots) were abundant in 
the subcutaneous tissue (outlined in grey). At day 21 (Figure 3.37b) inflammatory cells   
overlapped the areas outlined by the host (Outlined in red) and the donor tendon 
(Outlined in green). At Day 90 (Figure 3.37c) minimal inflammatory cells were cells both 
in tendon and in the subcutaneous tissues. 
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Figure 3.47 -Spatiotemporal distribution of Inflammatory cell -Macrophage (Blue) and CD45 positive 
cells(Yellow) at day 3(top), day 21(middle) and Day90 (Bottom). Graft Green, Host tendon red, ST-Grey 
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3.2.8.2 Collagen synthesis 
 
Three Dimensional Reconstruction of serial sections (Figure 3. 48 a-c) showed that at 
Day 3 (Figure 3.48a) collagen synthesizing cells (outlined with yellow dots) were 
present in small numbers in the subcutaneous tissue and tendon   with no collagen 
synthesis seen in GFP positive donor tendon cells (outlined with blue dots). At day 21 
(Figure 3.38b) Hsp47 positive cells   crowded the areas outlined by the host (Outlined in 
red) and the donor tendon (Outlined in green). Marked overlapping was seen between 
GFP positive and Hsp47 positive cells. At Day 90 (Figure 3.37c) minimal inflammatory 
cells were cells both in tendon and in the subcutaneous tissues. 
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Figure 3.48 -Spatiotemporal distribution of GFP positive cells (Blue) and cells synthesizing collagen 
(Yellow) at day 0) top, day21 and day90 (Bottom). Graft Green, Host tendon red, ST-Grey 
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3.2.8.9 Overall summary- tendon grafting 
The time points selected of 3 days, 21 days and 90 days related to the phases of wound 
healing corresponding to the inflammatory phase, peak synthesis phase, and end of 
remodelling phase as noted in previous tendon wounding experiments. The pattern of 
the cellular changes following grafting was similar between autografts and syngenic 
grafts however the amplitude of cellular activity did differ between certain aspects of 
the healing process. The pattern of inflammation following grafting showed an intense 
inflammatory reaction in the subcutaneous tissue at Day 3, followed by an increase in 
inflammatory cells in the host tendon and grafted tendon at Day 21, which gradually 
diminished but did not reach baseline levels in all tissues at Day 90. 
 
The pattern of cellular proliferation showed a gradual increase in BrdU staining from 
control levels after grafting that mainly occurred in the subcutaneous tissues, whereas 
BrdU expression peaked in the host tendon and the tendon graft at Day 21 and 
gradually diminished at Day 90. Collagen synthesis as measured by Hsp 47 expression 
was increased in the subcutaneous tissues initially at 3 days followed by increased 
expression in the host tendon and tendon graft at Day 21, reducing to baseline levels at 
Day 90. Apoptosis as measured by TUNEL expression showed a gradual increase from 
control non injured tissues at Day 3 reaching a peak at Day 21 and diminishing by Day 90. 
Lumen related Alpha- SMA staining showed a significant increase in the vascularity of 
the subcutaneous tissue at Day 3 compared to control unwounded tendons. 
Vasculartity remained at high levels at Day 21 and at Day 90. 
 
By grafting C57 tendon onto a GFP host there was a marked increase in GFP expression 
at Day 3 which could be attributed to by host inflammatory cells. It was also evident 
that the C57 graft became populated by host GFP cells by day 21 with the GFP 
expression in grafted tendon being greater than that of host tendon. By grafting GFP 
tendon onto a C57 host, the number of GFP cells increased per unit area by Day 21. 
However GFP expression rapidly disappeared by Day 90 
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3.3 Results- Construct testing 
3.3.1 Results- Fibrin Construct Grafting 
 
The fibrin- construct disintegrated within 72 hours. GFP stain showed loss of GFP 
positive cell by Day 3 (Figure 3.50) . The construct   was encapsulated within a fibrin clot 
and the cells lost its oval tendon-fibroblast like appearance and became rounded. The 
construct and its surrounding subcutaneous tissue became hypercellular indicating an 
inflammatory infiltrate (Figure 3.49) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.49 - Day 3 of construct grafting-Top H&E stained section and bottom GFP stained section –
Construct outlined in black. Arrows indicate sutures used to secure construct. NO GFP positive cells are 
seen. Magnification.x10; Bar-200 µm 
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Figure 3.50 -GFP stained construct grafting- Day 0, Day 3 and Day 7 (Top to bottom). Construct appears to 
have disintegrated very early with loss of GFP stain within 3 days. Construct outline in black, Arrow 
indicating the securing sutures; Magnification x 5 , Scale Bar-500 µm 
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3.3.2 PCL Construct testing 
 
The PCL construct melted at 60 degrees and therefore routine wax processing could 
not be used to study their fate. SEM studies showed   that the construct acted as a 
scaffold and new tendon-like   tissue was being laid down around it by Day 21. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.51 - SEM micrographs of a single 3D bundle grafted into the created defect of a mouse Achilles 
tendon taken at Time Zero (top) and  3 weeks   (Bottom) after implantation. Time zero identifies the 
potential position of the bundle within the tendon (magnification x100), and at 3 weeks potentially new 
tissue which has encapsulated the bundle can be seen (magnifications x2500). Where C=Construct, T= 
tendon;  Surgery by Nawsheen Alam, SEM by Lucy Bosworth 
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Chapter Four 
Discussion 
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4.1 Anatomy of the mouse Achilles tendon 
 
Rodent models   are   commonly used mammalian models for in vivo studies due to their 
availability, size, low cost, ease of handling, and fast reproduction rate.  The availability 
of a large number of genetic species allows for identification of therapeutic targets as 
the mouse genome is similar to the human genetic map (Mouse Genome sequence 
consortium, Nature 2002). The small size of mouse tendons and ligaments has so far 
limited their use for tendon research. This trend is now changing (Chhabra et al., 2003; 
Hasslund et al., 2008; Mikic et al., 2006; Wong et al., 2009) in order to take advantage of 
the large number of inbred and outbred strains of mice (Jackson Lab, USA). The 
availability of the GFP species which offers easy tracking of cells encouraged us to 
develop a mouse model which will allow us to study cellular events following 
transplantation of tendon either in the form of a graft or an engineered construct. 
 
Recent studies have used the mouse flexor tendon to study the biology of sutures, 
flexor tendon healing and adhesion formation (Wong et al., 2006b; Wong et al., 2009).   
The mouse flexor tendon has also been used to study adhesions after   tendon grafting 
(Hasslund et al., 2008).  A larger model would provide a   technically reproducible model 
for the study of tendon and construct grafting. The flexor tendon is an intrasynovial 
tendon and the majority of the tendon grafts used in clinical practice is extrasynovial in 
origin. Therefore, the Achilles tendon of the mouse was studied to establish a new 
model for the study of   tendon grafting biology.  
 
 A number of similarities were found between the anatomy of the mouse and the 
human Achilles tendon in terms of its origin, insertion and rotation. In both mice and 
human the Achilles tendon was formed by the tendons of gastrocnemius and soleus 
and inserted into the posterior surface of the calcaneum bone. In mouse however, the 
plantaris tendon was present consistently in all animals and lay on the posterior aspect 
of the Achilles tendon. The tendon was covered by loose connective tissue, the 
paratenon. This was particularly obvious anterior to the tendon and created a plane 
between the Achilles tendon and the deep flexor compartment in which blood vessels 
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were seen to traverse.  In the distal part, the loose areolar tissue widened and 
contained an area of fatty tissue. In human, a similar   area is known as Kaegar’s pad of 
fat (Benjamin et al., 2008; Theobald et al., 2006) and is thought to contribute to 
reducing the risk of tendon kinking. In loaded Achilles tendon the fat pad slides 60% 
further into the retrocalcaneal bursa providing lubrication and preventing  friction 
injuries (Ghazzawi et al., 2009). On the posterior aspect, thin fascial extensions were 
seen passing from the skin into the connective tissue sleeve around the Achilles tendon. 
This fascial envelope and connections may play an important role in the gliding of the 
Achilles tendon. It probably represents the microvacuolar system described by 
Guimberteau (Guimberteau et al., 2010) allowing  the tendon to move without any 
distortion of the skin. Alcian blue staining showed that the fascial envelope is high in 
proteoglycans and has a loose areolar distribution. The increase in proetoglycans at the 
region of union of soleus and gastrocnemius may play a role in  lubrication of the  
bundles of adjoining collagen to move over each other as speculated by Vogel (Vogel 
and Peters, 2005). The tendon proper shows no obvious areas of fibrocartilaginous 
zones. At the insertion region of the Achilles tendon definite areas of fibrocartilage 
were seen. 
 
The insertion region of the Achilles tendon has been studied in detail in cadavers (Milz 
et al., 2002; Rufai et al., 1995). Similar to human Achilles tendon, the mice Achilles 
tendon was found to be separated from the calcaneum by the retorcalcaneal bursa just 
above its insertion. The bursa together with its fibrocartilaginous walls is thought to 
protect the distal most part of the tendon from friction injuries during dorsiflexion of 
the ankle.  Thickening of the epitenon was seen at the concave and convex surface of 
the tendon, where the tendon was in contact with the surface and changing direction 
to insert in the bone. The thickening of the epitenon or endotenon have previously 
been described for wrap- around tendons (Benjamin et al., 1995). Benjamin et al. 
speculate that the thickening in the epitenon or endotenon may play a role in 
protecting tendon vasculature. 
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Alpha-Smooth muscle actin, an isoform of actin  that is typical of smooth muscle cells 
have been demonstrated in the cytoplasm of pericytes, a cell residing in the 
endothelieal layer of blood vessels. Alpha SMA stain of the Achilles tendon showed that 
the tendon substance was avascular. Non vessel related alpha SMA positive cells were 
found in the epitenon of   normal Achilles tendon which   may   represent presence of 
myofibroblasts. These cells have previously been implicated in remodeling of injured 
tendon  (Weiler et al., 2002). Abundant blood vessels were seen in the loose areolar 
tissue anterior to the tendon.  The relatively larger caliber vessels that appear to be 
contributing to the smaller vessels passing into the mesotenon is likely to be the 
posterior tibial vessels. Human cadaveric studies have shown  that the Achilles tendon 
receives blood supply from musculotendinous and  osseotendinous junctions(Ahmed et 
al., 1998; Carr and Norris, 1989) and also receives supply from posterior tibial vessels 
(Ahmed et al., 1998) through the mesotenon.  A second large caliber vascular bundle 
was seen closely related to the tendon but did not give off   any direct branches to the 
tendon. This group of large caliber vessels could represent the saphenous vascular 
bundle. Serial cross sections showed a uniform number of blood vessels in the 
mesotenon at all levels which is in keeping with previous reports by Ahmed et al.  
(Ahmed et al., 1998). This is in contrast to intrasynovial flexor tendon which  has been 
shown to receive segmental blood supply (Peacock, 1959; Zhang et al., 1990). 
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4.2 Biology of tendon grafting 
 
The practice of tendon grafting continues to be a useful technique for the 
reconstruction of damaged segments of tendon and for the reconstruction of 
ligaments. The biology of tendon graft integration bears some similarities to healing of 
injured tendons but also follows a cellular repopulation phenomenon particular to 
grafted tissue.  
 
Our study of syngenic GFP tendon grafting showed that no graft cell was detected at 
day 90. Kubo and co-workers  performed confocal studies of GFP positive grafts that  
have yielded results similar to our study (Iwata et al., 2008; Kobayashi et al., 2005) while 
a recent study by the same group suggested that graft cells disappear by day 7 (Tachiiri 
et al., 2010). The disparity between the time lines was not explained but variation in 
surgical technique may have contributed to the earlier disappearance of the graft cells.   
 
It is also possible that some of the graft cells persist but fail to express GFP.  Insitu 
hybridization study of sex mismatched tendon grafting reported a delayed repopulation 
by recipient cells between 12 and 30 weeks (Thorfinn et al., 2009). Thorfinn used 
tendons reseeded with cells which had been expanded in vitro, therefore may be less 
immunogenic and may not respond to loss of mechanical integrity in a manner similar 
to intrinsic tendon cells. Reseeding may also have led to a residual acellular area in the 
tendon core due to lack of cell penetration which may also have contributed to the 
delay in cellular repopulation. Tendon grafting studies of mice flexor tendon have 
shown that acellular freeze dried allografts  are repopulated by 42 days (Hasslund et al., 
2008). The control autografts in Hussland’s study showed chronological events similar 
to our study with hypercellularity at day 28 but cellular repopulation could not be 
identified in the autografts. Sex mismatched syngenic studies are needed to clarify this 
point of interest. 
 
The benefit of our DAB based immunohistological study was that it allowed us to see 
the cellular events in relation to the complete architecture of the leg and draw 
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conclusions regarding the spatiotemporal orientation of cells. The position of the graft 
could be identified with some ease by the GFP stain and the presence of the proximal 
and distal suture up to Day 21. After this time point   only the position of the two sutures 
allowed for the continued verification of the area of the graft. Our study was different 
from the above studies in terms of the design as we used a  patch/ onlay  graft while the 
above studies used either a  tendon to bony insertion (Iwata et al., 2008; Kobayashi et 
al., 2005) or end to end repair (Hasslund et al., 2008). As Achilles tendon is a weight 
bearing tendon, removal and replacement of a complete segment without 
immobilisation of the whole leg, may have impaired mice ambulation leading to poor 
health. On the other hand  an onlay  graft offered a broader insight of cellular events as 
cell traffic was both from side to side and from the stumps. One of the limitations of the 
model could be   that using a patch graft excluded the role of direct mechanical forces 
on the early remodelling of the graft. Previous studies have shown that creating a 
window in extensor tendon  led to hypertrophy of the rest of the tendon until the 
window is filled with fibrillar collagen and incorporated in the tendon (Matthew et al., 
1987). The authors speculated that the nonlesional part of the tendon responded to the 
added stress by the formation of more collagen as well as the lesional part. In our study 
it is likely that the grafted tendon segment was not involved in load transmission in the 
early part of healing. At Day 3 the tendon graft appeared to be separated from the rest 
of the tendon by a fibrin clot. Around Day 21 the graft appeared to be incorporated 
inside the tendon with significant rise in collagen synthetic activity both in the graft and 
the host tendon. The boundary of the graft was indistinct. The collagen synthetic 
activity at Day 21 may represent the redistribution of load throughout the tendon in 
keeping with Matthew’s findings of the appearance of small fibrils in the non-lesion 
area between 1o-30 days.  
 
At Day 21 the graft was hypercellular and had both abundant rounded and oval cells 
which may represent inflammatory and tendon cells respectively. Positive GFP staining 
suggested that graft cells were   viable until Day 21. High level of Hsp47 activity in the 
area of the graft at Day 21 also indicates that cells are very active atleast until this stage 
of healing. The early results are similar to histological  reports by  Mason and Shearon 
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(Mason and Shearon, 1932) and Potenza (Potenza, 1964) who showed that the graft 
remained viable throughout the healing period. In our study, the disappearance of GFP 
positive cells from the GFP syngenic grafts and the number of apoptotic cells in the 
graft at Day 21 suggests that the cells of the graft have a finite life after transplantation. 
The matrix turnover of the graft was not studied and therefore cannot be commented 
upon. But Hsp 47 activity in and around the graft at Day 21 suggest deposition of new 
matrix by cells in the area of the graft. Therefore we suggest that the graft cells are 
both viable and metabolically active in the early phase of healing.  
 
The mechanism of disappearance of graft cells is not yet known. It is possible that loss 
of intercellular communication leads to  inability of the tendon graft to respond to 
stress (McNeilly et al., 1996) which then undergo a process of apoptosis (Egerbacher et 
al., 2008; Kawabata et al., 2009). Apoptosis was more marked in syngenic grafts than 
autologous grafts and this may be due to either immunogenicity of the GFP grafts or a 
disparity of size compared to autologous grafts which were perfect fits in their host 
environment as they were replaced orthotopically. Immunogenic reaction between GFP 
and their syngenic counterpart has rarely been reported. Matsuo reported rejection of 
full thickness dorsal  skin graft  between GFP and C57BL/6 mice, which was then 
avoided by using tail skin  (Matsuo et al., 2007).  The biological processes observed in 
both syngenic and autologous grafts were parallel in terms of timing. Moreover no 
signs of rejection were seen either clinically or macroscopically all of which provides 
argument against an immunogenic response to the syngenic graft. 
 
An interesting and unexplained phenomenon in the graft cells was observed at Day 21. 
The GFP stain in GFP positive syngenic graft was more intense compared to day 3 and 
the cells appeared to be crowding together. The GFP in mammalian cells is distributed 
across cytoplasm and nucleus. One explanation may be that the initiation of apoptosis 
which is marked by cell condensation increases the intensity of the GFP signal. It may 
also be possible that redistribution of mechanical load leads to graft cells trying to 
realign themselves in the line of stress. There may also be a movement of cells away 
from the sutures though this was not obvious. The sutures were put in the long axis of 
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the tendon and therefore acellular zones occurring due to the  gripping component of 
the  suture was avoided (Wong et al., 2010). Alternatively the matrix may have been 
degrading causing the cells to crowd together. 
 
The function of cells of the graft is not clear. In our study the very high level of Hsp47 
activity of   the tendon cells of the graft at Day 21 suggests that cells of the grafted 
tendon are very active and participates in neo tendon formation. Collagen synthesis 
peaked at Day 21 which is in keeping with the traditional phases of healing. Though the 
graft cells disappear after this stage, their role in the early phase of healing appears to 
be of significance for the remodelling of tendon. An earlier peak of synthetic activity at 
day 3 and day 7 post grafting has been reported for GFP chimeric rat tendon grafting 
models (Kajikawa et al., 2008; Tachiiri et al., 2010).  There may be an interspecies 
variability between mice and rat or the GFP cells in the rat model may be more 
immunogenic. The difference in the study designs may account for the difference in 
time frames with our study.  In our study we applied a   patch graft to a partial window 
model and therefore mechanical forces involved in the remodelling process were very 
different from other tendon grafting experiments and may not be comparable. 
 
Three dimensional reconstruction of serial histological sections showed overlapping of 
collagen synthetic activity with the GFP positive graft cells. This suggests that graft cells 
are not quiescent and have an active role in healing. This may explain why cellular 
autografts appear to have more strength than acellular allografts (Romanini et al., 2010; 
Scheffler et al., 2008). In sheep model of Anterior Cruciate Ligament Reconstruction 
recellularization and revascularization was significantly delayed in the allograft  at 6 and 
12 weeks of healing, while significantly lower structural and mechanical properties were 
found at 52 weeks (Scheffler et al., 2008).Chong reported  contradicting results  and 
showed no difference existed between the tensile strength of normal and acellularised 
tendons (Chong et al., 2009). Less adhesion formation was reported as an added 
advantage in acellular tendon grafts (Hasslund et al., 2008). The debate may continue 
as evidence on both sides   continues   to mount. Our study provides evidence in favour 
of cellular grafts and it is possible that if cells can be encouraged to start synthesizing 
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collagen at a higher rate and at an earlier time point, such as by the use of mechanical, 
electrical or factorial stimulation, construct and graft remodelling may be expedited. 
 
Apoptosis has been shown to be a part o f the healing process of wounded tendons. Lui 
(Lui et al., 2007) reported that TUNEL positive cells peaked at 28 days following tendon 
wounding while Wong  (Wong et al., 2009) reported a peak at 84 days in a mice tendon 
adhesion model. A recent study reports a much earlier peak in apoptosis in the healing 
tendons at day 3, followed about 10 days later by the peak proliferation period (Wu et 
al., 2010).Wu also found that apoptosis was inhibited  between 2 and 4 weeks. It 
appears that apoptosis plays a significantly greater role in tendon graft healing 
compared to healing of wounded tendons. In our study TUNEL positive cells were 
present in the tendons at day 3, increased significantly by day 21 and continued to be 
present at day 90. Apoptotic cells were present both at the area of the donor tendon 
and in the host tendon as well as surrounding peritendinous areas. Apoptosis therefore 
appears to be an integral part of cellular repopulation in tendon graft healing. 
Apoptosis may be triggered by loss of mechanical integrity and the need for 
realignment by the tendon cells. Apoptosis has been shown to be induced both by  
mechanical loading of  intact tendon (Scott et al., 2005) or by the lack of it (Egerbacher 
et al., 2008). Egerbacher et al. suggest that loss of homeostatic tension causes an 
alteration in cell-matrix interactions leading to an in increase in apoptosis. In our study a 
slightly higher level of apoptosis was seen in syngenic grafts compared to autologous 
grafts where size and shape mismatch was minimum. The subcutaneous tissue and 
peritendinous area showed very high level of apoptotic activity from Day 3. The large 
number of inflammatory cells present in the subcutaneous tissue probably undergoes 
apoptosis leading to the high TUNEL activity in this area (Brown et al., 1997).  Some of 
the apoptotic activity in the tendon at Day 21 can also be contributed to the death of 
invading  inflammatory cells (Homburg and Roos, 1996).  
 
Several studies have reported a close association between apoptosis and cell 
proliferation (Lui et al., 2007; Wu et al., 2010). Lui reported that as well as TUNEL 
positive cells, the level of PCNA positive fibroblast like cells remained high at day 28 
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indicating a high level of cellular proliferation.  They speculate that this association may 
be suggestive of  an attempt of the cells to repair DNA during apoptosis and that cells 
undergo abortive events in the early mitotic phases, therefore staining positive for both 
TUNEL and PCNA. The results of this study are comparable to our finding of apoptotic 
and proliferative cells in tendon graft healing, both of which peaked at Day 21. The 
number of BrdU positive cells in the tendon tissue peaked at Day 21, while the number 
of BrdU positive cells was high in the subcutaneous tissue from Day 3 to Day 90, 
peaking at Day 21. At Day 3 most of the BrdU positive cells in the subcutaneous tissue 
are likely to be inflammatory in nature. In the early period the hypercellular 
subcutaneous tissue has marked positive staining for inflammatory markers-CD45, Ly6G 
and F4/80 which respectively represent pan leukocyte, neutrophils and macrophages. 
At Day 3 the number of CD45 and Ly6G positive cells are higher than the F4/80 stained 
cells. Only a very small number of inflammatory cells are seen in the tendon substance 
at this time. But by Day 21 there is a significant rise in the number of neutrophils and 
macrophages in the tendon substance and this is more marked in the area of the graft.  
Both CD45 and Ly6G positive cells are significantly greater in the syngenic graft 
compared to autografts which may be either due to early rejection of the syngenic 
graft, which could not be completely ruled out or experimental conditions such as size 
mismatch. The short interval between harvesting the syngenic graft and placing it in the 
host tendon compared to no time gap between harvesting and securing the autologous 
graft may also   have contributed to the higher inflammatory response.  
 
At Day 21 the inner tendon core appeared relatively hypocellular compared to its 
surrounding tendon tissue. The difference in the level of inflammatory cells between 
the outer and inner tendon has previously been noted in Anterior Cruciate Ligament  
reconstruction (Kawamura et al., 2005). It appears that the tendon core lags behind the 
outer tendon in terms of inflammation and remodelling. The role of the inflammatory 
cells inside the tendon substance is not obvious.  But the presence   of these cells in the 
synthetic phase of healing may be of significance.  The reported increase in ED2 positive 
mature tissue macrophages at the later stages of healing suggest that these cells may 
have a role in graft healing. In our study their presence coincided with a high synthetic 
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activity in the graft area at day 21 which is also indicative of a reparative role. F4/80 
positive macrophages were greater in autografts suggesting greater coordinated 
healing and earlier remodelling of tissues. A possible explanation may be that the 
inflammatory cells release cytokines and growth factors that stimulate apoptosis while 
also releasing factors to stimulate matrix synthesis. Macrophages  have been shown  to 
produce cytokines that can contribute to healing by induction of angiogenesis, 
fibroblast proliferation, and extracellular matrix synthesis and degradation (Nathan, 
1987). Studies of macrophage depletion following Anterior Cruciate Ligament 
reconstruction have shown  improved morphologic and biomechanical properties at the 
healing of  tendon-bone interface (Hays et al., 2008) while  also showing significant 
reduction in cellular proliferation(Godbout et al., 2010). The exact role of various 
inflammatory cells and their interaction should be investigated further.  
 
The intense inflammatory reaction in the subcutaneous tissue at Day 3 is accompanied 
by a marked increase in the number of blood vessels which is in keeping with the 
normal events of the inflammatory phase of wound healing (Wong et al., 2009). At Day 
21 the previously avascular tendon graft and host tendon show positive staining for 
lumen associated alpha-SMA indicating that the graft is vascularised and this is 
maintained even at Day 90. This suggest vascularisation is accompaniment of  graft 
healing which is in keeping with previous reports (Gelberman et al., 1992a). The blood 
vessels have been shown to be associated with bone marrow derived cells (Zantop et 
al., 2006)  and are likely to be responsible for the influx of inflammatory cells in the 
tendon at Day 21. 
 
Our study showed   that cells of tendon graft undergo cellular repopulation and this is 
associated with an influx of inflammatory cells, apoptosis, proliferation, and collagen 
synthesis.  Cellular events in the tendon lagged behind events in the subcutaneous 
tissue and only reached comparable levels around Day 21. We suggest that earlier 
repopulation may influence graft healing positively and healing time may be accelerated 
by targeted manipulation of graft cells. This hypothesis would be tested in future 
investigations. Our study also indicates that cellular grafts and constructs are likely to 
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provide earlier remodelling due to the active participation of the graft cells leading to 
earlier biomechanical recovery and future work will also focus in this area. 
 
4.3 Application of the model for testing of novel tendon constructs and 
suggestions for future work 
 
In 1999, the U.S. National Committee on Biomechanics proposed that  in vitro 
development of tissue engineered constructs should be tested in vivo to determine 
what signals cells experience in vivo as they interact (Butler et al., 2000). In vitro 
mechanical testing and cell culture assays provide key information to the improvement 
and tuning of the construct. However, experimental testing in an appropriate animal 
model remains an essential step to identify the response of the construct to the 
biological environment. 
 
If a construct contains implanted cells the viability and mobility of the implanted cells is 
of primary consideration. Outcomes of the implanted cells may  include, quiescence, 
proliferation, apoptosis and ischemic death (Carpenter and Hankenson, 2004). If the 
construct is acellular the fundamental question is that of cellular repopulation and 
biological integration.  
 
We successfully used the mouse Achilles tendon model for in vivo testing of two very 
different engineered constructs. The small nature of these constructs which are at early 
stages of their development meant that the mouse Achilles was a perfect model for 
testing these constructs. The cellular fibrin construct was developed from the tail 
tendon of GFP mouse and the viability of the cells could be followed in time using GFP 
immunohistochemistry. Unfortunately the fibrin graft disintegrated early in the 
experiments and by day 3 no GFP cells could be seen. The benefit of in vivo testing is 
that it allows for identification of such problems early in tissue engineering and leads to 
revisiting of the in vitro stages. In this case several theories were considered. Tension 
has been shown to be essential for the formation of the fibripositor positive fibrin 
construct (Kapacee et al., 2008). It may be possible that when the constructs are 
divided from their pinned attachments, the loss of tension leads to rapid disintegration 
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of the delicate construct. It may also be possible that the fibrin based construct lacked 
an enveloping cell layer around the construct. The in vivo environment may have 
recognised this as a fibrinous material and caused an early degradation. If the cells in 
the construct can be manipulated to resist the initial   invasion of the inflammatory cells, 
the fibripositor positive cells may get enough time to adapt to their new environment. 
Further in vitro experiments of the construct are currently in progress which may be 
followed by in vivo testing. 
 
The second construct was chosen to test if the model would allow us to identify 
seeding of acellular scaffolds and the timeline of events. The advantage of the 
electrospun Polycaprolactone (PCL) construct is that it has tendon- like longitudinally 
oriented fibers which are very light weight with a large surface area, allowing a greater 
degree of cell attachment to occur. Polycaprolactone (PCL) is a  biocompatible and 
bioresorbable 
 polyester that has  a slower degradation rate than other bioresorbable polymers, which  
may allow seeded cells time to generate and organise Extracellular Matrix (Bosworth et 
al., 2008).  Unfortunately the small number of animals and the low melting point of the 
construct did not allow us to carry out histological investigations. The harvested 
tendons were investigated with Scanning Electron Microscopy (SEM) and in situ, the 
architecture of the PCL construct appeared to have some similarities to normal tendon. 
At Day 21 there appeared to be potentially new tissue surrounding the scaffold 
indicating incorporation of the construct. Cellular seeding could not be determined. 
Further in vitro  manipulation of the PCL construct is in progress  and future in vivo 
experiments will be carried out using low melting point wax processed histology, 
immunohistochemistry and SEM. 
  
The investigations carried out to test a cell-based and an acellular construct yielded only 
preliminary results. But the study proved that the mouse Achilles tendon model could 
be successfully used to carry out in vivo construct testing. It also showed that in vitro 
development of engineered tissue or biomaterial should run alongside testing in an 
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appropriate animal model as this allows for problems to be detected early and changes 
to be made in study design from the early stages. 
 
The Mouse Achilles tendon offers an economic and reproducible model   for the study 
of tendon injuries. The availability of GFP species with cell tracking facilities allowed for 
the development of a versatile tendon grafting model which can also be used to test 
biomaterials. 
 
Tendon graft cells remain viable and metabolically active in the early phases of graft 
integration. The cells of the graft   appear to undergo a process of apoptosis and are 
completely replaced by host cells in the later phase.  The interaction between cell 
activity and cell death plays a significant role in the remodeling and reorganization 
of the tendon. We suggest that cellular grafts may offer advantages over acellular 
grafts in terms of earlier   remodeling leading to   a shorter recovery period. 
 
Early results of an engineered cell-based fibrin construct did not provide sufficient 
persistence, while acellular constructs showed some potential as a viable scaffold 
material.  The Mouse Achilles tendon proved to be an appropriate model for the in 
vivo testing of tendon constructs. 
158 
 
 
 
 
 
 
 
 
 
 
Chapter Five 
Bibliography 
159 
 
 
Abrahamsson SO, Gelberman RH, Amiel D, Winterton P, Harwood F. 1995. 
Autogenous flexor tendon grafts: fibroblast activity and matrix remodeling 
in dogs. J Orthop Res 13(1):58-66. 
Ahmed IM, Lagopoulos M, McConnell P, Soames RW, Sefton GK. 1998. Blood supply 
of the Achilles tendon. J Orthop Res 16(5):591-596. 
Amiel D, Harwood FL, Gelberman RH, Chu CR, Seiler JG, 3rd, Abrahamsson S. 1995. 
Autogenous intrasynovial and extrasynovial tendon grafts: an experimental 
study of pro alpha 1(I) collagen mRNA expression in dogs. J Orthop Res 
13(3):459-463. 
Amiel D, Kleiner JB, Akeson WH. 1986a. The natural history of the anterior cruciate 
ligament autograft of patellar tendon origin. Am J Sports Med 14(6):449-
462. 
Amiel D, Kleiner JB, Roux RD, Harwood FL, Akeson WH. 1986b. The phenomenon of 
"ligamentization": anterior cruciate ligament reconstruction with 
autogenous patellar tendon. J Orthop Res 4(2):162-172. 
Ark JW, Gelberman RH, Abrahamsson SO, Seiler JG, 3rd, Amiel D. 1994. Cellular 
survival and proliferation in autogenous flexor tendon grafts. J Hand Surg 
Am 19(2):249-258. 
Arnoczky SP, Tarvin GB, Marshall JL. 1982. Anterior cruciate ligament replacement 
using patellar tendon. An evaluation of graft revascularization in the dog. J 
Bone Joint Surg Am 64(2):217-224. 
Ashley FL, McConnell DV, Polak T, Stone RS, Marmor L. 1964. An Evaluation of the 
Healing Process in Avian Digital Flexor Tendons and Grafts Following the 
Application of an Artificial Tendon Sheath. Plast Reconstr Surg 33:411-421. 
Badylak S, Arnoczky S, Plouhar P, Haut R, Mendenhall V, Clarke R, Horvath C. 1999. 
Naturally occurring extracellular matrix as a scaffold for musculoskeletal 
repair. Clin Orthop Relat Res(367 Suppl):S333-343. 
Badylak SF, Tullius R, Kokini K, Shelbourne KD, Klootwyk T, Voytik SL, Kraine MR, 
Simmons C. 1995. The use of xenogeneic small intestinal submucosa as a 
160 
 
biomaterial for Achilles tendon repair in a dog model. J Biomed Mater Res 
29(8):977-985. 
Banes AJ, Donlon K, Link GW, Gillespie Y, Bevin AG, Peterson HD, Bynum D, Watts S, 
Dahners L. 1988. Cell populations of tendon: a simplified method for 
isolation of synovial cells and internal fibroblasts: confirmation of origin and 
biologic properties. J Orthop Res 6(1):83-94. 
Bedi A, Kawamura S, Ying L, Rodeo SA. 2009. Differences in tendon graft healing 
between the intra-articular and extra-articular ends of a bone tunnel. HSS J 
5(1):51-57. 
Benjamin M, Kaiser E, Milz S. 2008. Structure-function relationships in tendons: a 
review. J Anat 212(3):211-228. 
Benjamin M, Qin S, Ralphs JR. 1995. Fibrocartilage associated with human tendons 
and their pulleys. J Anat 187 ( Pt 3):625-633. 
Benjamin M, Ralphs JR. 1998. Fibrocartilage in tendons and ligaments--an 
adaptation to compressive load. J Anat 193 ( Pt 4):481-494. 
Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC, Sonoyama W, Li L, Leet AI, Seo 
BM, Zhang L, Shi S, Young MF. 2007. Identification of tendon 
stem/progenitor cells and the role of the extracellular matrix in their niche. 
Nat Med 13(10):1219-1227. 
Birk DE, Mayne R. 1997. Localization of collagen types I, III and V during tendon 
development. Changes in collagen types I and III are correlated with 
changes in fibril diameter. Eur J Cell Biol 72(4):352-361. 
Birk DE, Trelstad RL. 1986. Extracellular compartments in tendon morphogenesis: 
collagen fibril, bundle, and macroaggregate formation. J Cell Biol 103(1):231-
240. 
Bosworth L, Clegg P, Downes S. 2008. Electrospun nanofibres of polycaprolactone, 
and their use for tendon regeneration. Int J Nano and Biomaterials Vol. 
1(3):263–279. 
Broughton G, 2nd, Janis JE, Attinger CE. 2006. Wound healing: an overview. Plast 
Reconstr Surg 117(7 Suppl):1e-S-32e-S. 
161 
 
Brown DL, Kao WW, Greenhalgh DG. 1997. Apoptosis down-regulates inflammation 
under the advancing epithelial wound edge: delayed patterns in diabetes 
and improvement with topical growth factors. Surgery 121(4):372-380. 
Butler DL, Goldstein SA, Guilak F. 2000. Functional tissue engineering: the role of 
biomechanics. J Biomech Eng 122(6):570-575. 
Butler DL, Juncosa-Melvin N, Boivin GP, Galloway MT, Shearn JT, Gooch C, Awad H. 
2008. Functional tissue engineering for tendon repair: A multidisciplinary 
strategy using mesenchymal stem cells, bioscaffolds, and mechanical 
stimulation. J Orthop Res 26(1):1-9. 
Butler DL, Juncosa N, Dressler MR. 2004. Functional efficacy of tendon repair 
processes. Annu Rev Biomed Eng 6:303-329. 
Canty EG, Lu Y, Meadows RS, Shaw MK, Holmes DF, Kadler KE. 2004. Coalignment 
of plasma membrane channels and protrusions (fibripositors) specifies the 
parallelism of tendon. J Cell Biol 165(4):553-563. 
Canty EG, Starborg T, Lu Y, Humphries SM, Holmes DF, Meadows RS, Huffman A, 
O'Toole ET, Kadler KE. 2006. Actin filaments are required for fibripositor-
mediated collagen fibril alignment in tendon. J Biol Chem 281(50):38592-
38598. 
Cao Y, Liu Y, Liu W, Shan Q, Buonocore SD, Cui L. 2002. Bridging tendon defects 
using autologous tenocyte engineered tendon in a hen model. Plast 
Reconstr Surg 110(5):1280-1289. 
Carpenter JE, Hankenson KD. 2004. Animal models of tendon and ligament injuries 
for tissue engineering applications. Biomaterials 25(9):1715-1722. 
Carr AJ, Norris SH. 1989. The blood supply of the calcaneal tendon. J Bone Joint 
Surg Br 71(1):100-101. 
Chaplin DM. 1973. The vascular anatomy within normal tendons, divided tendons, 
free tendon grafts and pedicle tendon grafts in rabbits. A 
microradioangiographic study. J Bone Joint Surg Br 55(2):369-389. 
Chhabra A, Tsou D, Clark RT, Gaschen V, Hunziker EB, Mikic B. 2003. GDF-5 
deficiency in mice delays Achilles tendon healing. J Orthop Res 21(5):826-
835. 
162 
 
Chong AK, Riboh J, Smith RL, Lindsey DP, Pham HM, Chang J. 2009. Flexor tendon 
tissue engineering: acellularized and reseeded tendon constructs. Plast 
Reconstr Surg 123(6):1759-1766. 
Comley AS, Krishnan J. 1999. Donor site morbidity after quadriceps tendon harvest 
for rotator cuff repair. Aust N Z J Surg 69(11):808-810. 
Dejardin LM, Arnoczky SP, Ewers BJ, Haut RC, Clarke RB. 2001. Tissue-engineered 
rotator cuff tendon using porcine small intestine submucosa. Histologic and 
mechanical evaluation in dogs. Am J Sports Med 29(2):175-184. 
Derwin KA, Badylak SF, Steinmann SP, Iannotti JP. 2004. Extracellular matrix 
scaffold devices for rotator cuff repair. J Shoulder Elbow Surg 19(3):467-476. 
Egerbacher M, Arnoczky SP, Caballero O, Lavagnino M, Gardner KL. 2008. Loss of 
homeostatic tension induces apoptosis in tendon cells: an in vitro study. Clin 
Orthop Relat Res 466(7):1562-1568. 
Ertel AN. 1989. Flexor tendon ruptures in rheumatoid arthritis. Hand Clin 5(2):177-
190. 
Fenwick SA, Hazleman BL, Riley GP. 2002. The vasculature and its role in the 
damaged and healing tendon. Arthritis Res 4(4):252-260. 
Flynn JE, Wilson JT, Child CG, Graham JH. 1960. Heterogenous and autogenous-
tendon transplants. An experimental study of preserved bovine-tendon 
transplants in dogs and autogenous-tendon transplants in dogs. J Bone 
Joint Surg Am 42-A:91-110. 
Freilich AM, Chhabra AB. 2007. Secondary flexor tendon reconstruction, a review. J 
Hand Surg Am 32(9):1436-1442. 
Furie RA, Chartash EK. 1988. Tendon rupture in systemic lupus erythematosus. 
Semin Arthritis Rheum 18(2):127-133. 
Gelberman RH, Chu CR, Williams CS, Seiler JG, 3rd, Amiel D. 1992a. Angiogenesis in 
healing autogenous flexor-tendon grafts. J Bone Joint Surg Am 74(8):1207-
1216. 
Gelberman RH, Manske PR, Vande Berg JS, Lesker PA, Akeson WH. 1984. Flexor 
tendon repair in vitro: a comparative histologic study of the rabbit, chicken, 
dog, and monkey. J Orthop Res 2(1):39-48. 
163 
 
Gelberman RH, Seiler JG, 3rd, Rosenberg AE, Heyman P, Amiel D. 1992b. Intercalary 
flexor tendon grafts. A morphological study of intrasynovial and 
extrasynovial donor tendons. Scand J Plast Reconstr Surg Hand Surg 
26(3):257-264. 
Ghazzawi A, Theobald P, Pugh N, Byrne C, Nokes L. 2009. Quantifying the motion of 
Kager's fat pad. J Orthop Res 27(11):1457-1460. 
Gigante A, Specchia N, Rapali S, Ventura A, de Palma L. 1996. Fibrillogenesis in 
tendon healing: an experimental study. Boll Soc Ital Biol Sper 72(7-8):203-
210. 
Godbout C, Bilodeau R, Van Rooijen N, Bouchard P, Frenette J. 2010. Transient 
neutropenia increases macrophage accumulation and cell proliferation but 
does not improve repair following intratendinous rupture of Achilles 
tendon. J Orthop Res 28(8):1084-1091. 
Graf J, Schneider U, Niethard FU. 1990. [Microcirculation of the Achilles tendon and 
significance of the paratenon. A study with the plastination method]. 
Handchir Mikrochir Plast Chir 22(3):163-166. 
Grant WP, Sullivan R, Sonenshine DE, Adam M, Slusser JH, Carson KA, Vinik AI. 1997. 
Electron microscopic investigation of the effects of diabetes mellitus on the 
Achilles tendon. J Foot Ankle Surg 36(4):272-278; discussion 330. 
Guimberteau JC, Delage JP, McGrouther DA, Wong JK. 2010. The microvacuolar 
system: how connective tissue sliding works. J Hand Surg Eur Vol 35(8):614-
622. 
Gungormus C, Kolankaya D. 2008. Characterization of type I, III and V collagens in 
high-density cultured tenocytes by triple-immunofluorescence technique. 
Cytotechnology 58(3):145-152. 
Hagberg L, Heinegard D, Ohlsson K. 1992. The contents of macromolecule solutes in 
flexor tendon sheath fluid and their relation to synovial fluid. A quantitative 
analysis. J Hand Surg Br 17(2):167-171. 
Hanly JG, Urowitz MB. 1986. Tendon rupture in systemic lupus erythematosus. Ann 
Rheum Dis 45(4):349. 
164 
 
Hasslund S, Jacobson JA, Dadali T, Basile P, Ulrich-Vinther M, Soballe K, Schwarz 
EM, O'Keefe RJ, Mitten DJ, Awad HA. 2008. Adhesions in a murine flexor 
tendon graft model: autograft versus allograft reconstruction. J Orthop Res 
26(6):824-833. 
Hays PL, Kawamura S, Deng XH, Dagher E, Mithoefer K, Ying L, Rodeo SA. 2008. The 
role of macrophages in early healing of a tendon graft in a bone tunnel. J 
Bone Joint Surg Am 90(3):565-579. 
Heinemeier KM, Olesen JL, Haddad F, Langberg H, Kjaer M, Baldwin KM, Schjerling 
P. 2007. Expression of collagen and related growth factors in rat tendon and 
skeletal muscle in response to specific contraction types. J Physiol 582(Pt 
3):1303-1316. 
Hess GW. 2010. Achilles tendon rupture: a review of etiology, population, anatomy, 
risk factors, and injury prevention. Foot Ankle Spec 3(1):29-32. 
Holmes I. 1971. Variations in tendon cell morphology with animal, site and age. J 
Anat 108(Pt 2):305-309. 
Homburg CH, Roos D. 1996. Apoptosis of neutrophils. Curr Opin Hematol 3(1):94-
99. 
Hu G, Gura T, Sabsay B, Sauk J, Dixit SN, Veis A. 1995. Endoplasmic reticulum protein 
Hsp47 binds specifically to the N-terminal globular domain of the amino-
propeptide of the procollagen I alpha 1 (I)-chain. J Cell Biochem 59(3):350-
367. 
Iannotti JP, Codsi MJ, Kwon YW, Derwin K, Ciccone J, Brems JJ. 2006. Porcine small 
intestine submucosa augmentation of surgical repair of chronic two-tendon 
rotator cuff tears. A randomized, controlled trial. J Bone Joint Surg Am 
88(6):1238-1244. 
Ikawa M, Kominami K, Yoshimura Y, Tanaka K, Nishimune Y, Okabe M. 1995. A rapid 
and non-invasive selection of transgenic embryos before implantation using 
green fluorescent protein (GFP). FEBS Lett 375(1-2):125-128. 
Ippolito E, Natali PG, Postacchini F, Accinni L, De Martino C. 1980. Morphological, 
immunochemical, and biochemical study of rabbit achilles tendon at various 
ages. J Bone Joint Surg Am 62(4):583-598. 
165 
 
Iwata Y, Morihara T, Tachiiri H, Kajikawa Y, Yoshida A, Arai Y, Tokunaga D, 
Sakamoto H, Matsuda K, Kurokawa M, Kawata M, Kubo T. 2008. Behavior of 
host and graft cells in the early remodeling process of rotator cuff defects in 
a transgenic animal model. J Shoulder Elbow Surg 17(1 Suppl):101S-107S. 
Iwuagwu FC, McGrouther DA. 1998. Early cellular response in tendon injury: the 
effect of loading. Plast Reconstr Surg 102(6):2064-2071. 
Kajikawa Y, Morihara T, Sakamoto H, Matsuda K, Oshima Y, Yoshida A, Nagae M, 
Arai Y, Kawata M, Kubo T. 2008. Platelet-rich plasma enhances the initial 
mobilization of circulation-derived cells for tendon healing. J Cell Physiol 
215(3):837-845. 
Kajikawa Y, Morihara T, Watanabe N, Sakamoto H, Matsuda K, Kobayashi M, 
Oshima Y, Yoshida A, Kawata M, Kubo T. 2007. GFP chimeric models 
exhibited a biphasic pattern of mesenchymal cell invasion in tendon healing. 
J Cell Physiol 210(3):684-691. 
Kannus P. 2000. Structure of the tendon connective tissue. Scand J Med Sci Sports 
10(6):312-320. 
Kapacee Z, Richardson SH, Lu Y, Starborg T, Holmes DF, Baar K, Kadler KE. 2008. 
Tension is required for fibripositor formation. Matrix Biol 27(4):371-375. 
Karaoglu S, M BF, Woo SL, Fu YC, Liang R, Abramowitch SD. 2008. Use of a 
bioscaffold to improve healing of a patellar tendon defect after graft 
harvest for ACL reconstruction: A study in rabbits. J Orthop Res 26(2):255-
263. 
Kawabata H, Katsura T, Kondo E, Kitamura N, Miyatake S, Tanabe Y, Setoguchi T, 
Komiya S, Yasuda K. 2009. Stress deprivation from the patellar tendon 
induces apoptosis of fibroblasts in vivo with activation of mitogen-activated 
protein kinases. J Biomech 42(15):2611-2615. 
Kawamura S, Ying L, Kim HJ, Dynybil C, Rodeo SA. 2005. Macrophages accumulate 
in the early phase of tendon-bone healing. J Orthop Res 23(6):1425-1432. 
Kealey GP. 1997. Disease transmission by means of allograft. J Burn Care Rehabil 
18(1 Pt 2):S10-11. 
166 
 
Khan U, Edwards JC, McGrouther DA. 1996. Patterns of cellular activation after 
tendon injury. J Hand Surg Br 21(6):813-820. 
Kleiner JB, Amiel D, Harwood FL, Akeson WH. 1989. Early histologic, metabolic, and 
vascular assessment of anterior cruciate ligament autografts. J Orthop Res 
7(2):235-242. 
Kobayashi M, Watanabe N, Oshima Y, Kajikawa Y, Kawata M, Kubo T. 2005. The fate 
of host and graft cells in early healing of bone tunnel after tendon graft. Am 
J Sports Med 33(12):1892-1897. 
Kryger GS, Chong AK, Costa M, Pham H, Bates SJ, Chang J. 2007. A comparison of 
tenocytes and mesenchymal stem cells for use in flexor tendon tissue 
engineering. J Hand Surg Am 32(5):597-605. 
Lee CH, Huang GS, Chao KH, Wu SS, Chen Q. 2005. Differential pretensions of a 
flexor tendon graft for anterior cruciate ligament reconstruction: a 
biomechanical comparison in a porcine knee model. Arthroscopy 21(5):540-
546. 
Lim JK, Hui J, Li L, Thambyah A, Goh J, Lee EH. 2004. Enhancement of tendon graft 
osteointegration using mesenchymal stem cells in a rabbit model of anterior 
cruciate ligament reconstruction. Arthroscopy 20(9):899-910. 
Liu SH, Kabo JM, Osti L. 1995. Biomechanics of two types of bone-tendon-bone 
graft for ACL reconstruction. J Bone Joint Surg Br 77(2):232-235. 
Liu W, Chen B, Deng D, Xu F, Cui L, Cao Y. 2006. Repair of tendon defect with 
dermal fibroblast engineered tendon in a porcine model. Tissue Eng 
12(4):775-788. 
Lui PP, Cheuk YC, Hung LK, Fu SC, Chan KM. 2007. Increased apoptosis at the late 
stage of tendon healing. Wound Repair Regen 15(5):702-707. 
Lundborg G, Holm S, Myrhage R. 1980. The role of the synovial fluid and tendon 
sheath for flexor tendon nutrition. An experimental tracer study on 
diffusional pathways in dogs. Scand J Plast Reconstr Surg 14(1):99-107. 
Maeda M, Nakamura T, Fukui A, Koizumi M, Yamauchi T, Tamai S, Nagano-Tatsumi 
K, Haga S, Hashimoto K, Yamamoto H. 1999. The role of serum imbibition for 
skin grafts. Plast Reconstr Surg 104(7):2100-2107. 
167 
 
Maffulli N, Leadbetter WB. 2005. Free gracilis tendon graft in neglected tears of the 
achilles tendon. Clin J Sport Med 15(2):56-61. 
Manske PR, Lesker PA. 1984. Histologic evidence of intrinsic flexor tendon repair in 
various experimental animals. An in vitro study. Clin Orthop Relat 
Res(182):297-304. 
Marsolais D, Cote CH, Frenette J. 2001. Neutrophils and macrophages accumulate 
sequentially following Achilles tendon injury. J Orthop Res 19(6):1203-1209. 
Mason ML, Shearon CG. 1932. The process of tendon repair: An experimental study 
of tendon suture and tendon graft. Arch Surg 25:615. 
Mastrokalos DS, Springer J, Siebold R, Paessler HH. 2005. Donor site morbidity and 
return to the preinjury activity level after anterior cruciate ligament 
reconstruction using ipsilateral and contralateral patellar tendon autograft: 
a retrospective, nonrandomized study. Am J Sports Med 33(1):85-93. 
Matsuo S, Kurisaki A, Sugino H, Hashimoto I, Nakanishi H. 2007. Analysis of skin 
graft survival using green fluorescent protein transgenic mice. J Med Invest 
54(3-4):267-275. 
Matthew C, Moore MJ, Campbell L. 1987. A quantitative ultrastructural study of 
collagen fibril formation in the healing extensor digitorum longus tendon of 
the rat. J Hand Surg Br 12(3):313-320. 
Matthews P, Richards H. 1975. The repair reaction of flexor tendon within the digital 
sheath. Hand 7(1):27-29. 
Mayer L. 1916. The physiological method of tendon transplantation. I. Historical; 
Anatomy and Physiology of Tendons. Surgery, Gynaecology and Obstetrics 
22:183-197. 
McNeilly CM, Banes AJ, Benjamin M, Ralphs JR. 1996. Tendon cells in vivo form a 
three dimensional network of cell processes linked by gap junctions. J Anat 
189 ( Pt 3):593-600. 
Mikic B, Bierwert L, Tsou D. 2006. Achilles tendon characterization in GDF-7 
deficient mice. J Orthop Res 24(4):831-841. 
Milano G, Mulas PD, Ziranu F, Piras S, Manunta A, Fabbriciani C. 2006. Comparison 
between different femoral fixation devices for ACL reconstruction with 
168 
 
doubled hamstring tendon graft: a biomechanical analysis. Arthroscopy 
22(6):660-668. 
Milz S, Rufai A, Buettner A, Putz R, Ralphs JR, Benjamin M. 2002. Three-dimensional 
reconstructions of the Achilles tendon insertion in man. J Anat 200(Pt 2):145-
152. 
Moore MJ, De Beaux A. 1987. A quantitative ultrastructural study of rat tendon 
from birth to maturity. J Anat 153:163-169. 
Moore T, Anderson B, Seiler JG, 3rd. 2010. Flexor tendon reconstruction. J Hand 
Surg Am 35(6):1025-1030. 
Murphy KD, Mushkudiani IA, Kao D, Levesque AY, Hawkins HK, Gould LJ. 2008. 
Successful incorporation of tissue-engineered porcine small-intestinal 
submucosa as substitute flexor tendon graft is mediated by elevated TGF-
beta1 expression in the rabbit. J Hand Surg Am 33(7):1168-1178. 
Nathan CF. 1987. Secretory products of macrophages. J Clin Invest 79(2):319-326. 
Nisbet NW. 1960. Anatomy of the calcaneal tendon of the rabbit. J Bone Joint Surg 
Br 42-B:360-366. 
Nyyssonen T, Luthje P, Kroger H. 2008. The increasing incidence and difference in 
sex distribution of Achilles tendon rupture in Finland in 1987-1999. Scand J 
Surg 97(3):272-275. 
O'Ceallaigh S, Herrick SE, Bennett WR, Bluff JE, Ferguson MW, McGrouther DA. 
2007. Perivascular cells in a skin graft are rapidly repopulated by host cells. J 
Plast Reconstr Aesthet Surg 60(8):864-875. 
O'Ceallaigh S, Herrick SE, Bluff JE, McGrouther DA, Ferguson MW. 2006. 
Quantification of total and perfused blood vessels in murine skin autografts 
using a fluorescent double-labeling technique. Plast Reconstr Surg 117(1):140-
151. 
Oryan A, Shoushtari AH. 2008. Histology and ultrastructure of the developing 
superficial digital flexor tendon in rabbits. Anat Histol Embryol 37(2):134-140. 
Ouyang HW, Goh JC, Lee EH. 2004. Use of bone marrow stromal cells for tendon 
graft-to-bone healing: histological and immunohistochemical studies in a 
rabbit model. Am J Sports Med 32(2):321-327. 
169 
 
Peacock EE, Jr. 1959. A study of circulation in normal 
tendons and healing grafts. Ann Surg 149:415. 
Pickersgill CH, Marr CM, Reid SW. 2001. Repeatability of diagnostic ultrasonography 
in the assessment of the equine superficial digital flexor tendon. Equine Vet 
J 33(1):33-37. 
Potenza AD. 1962. Tendon healing within the flexor digital sheath in the dog. J Bone 
Joint Surg Am 44-A:49-64. 
Potenza AD. 1964. The Healing of Autogenous Tendon Grafts within the Flexor 
Digital Sheath in Dogs. J Bone Joint Surg Am 46:1462-1484. 
Romanini E, D'Angelo F, De Masi S, Adriani E, Magaletti M, Lacorte E, Laricchiuta P, 
Sagliocca L, Morciano C, Mele A. 2010. Graft selection in arthroscopic 
anterior cruciate ligament reconstruction. J Orthop Traumatol 11(4):211-219. 
Rowe RW. 1985. The structure of rat tail tendon. Connect Tissue Res 14(1):9-20. 
Rufai A, Ralphs JR, Benjamin M. 1995. Structure and histopathology of the 
insertional region of the human Achilles tendon. J Orthop Res 13(4):585-593. 
Scheffler SU, Schmidt T, Gangey I, Dustmann M, Unterhauser F, Weiler A. 2008. 
Fresh-frozen free-tendon allografts versus autografts in anterior cruciate 
ligament reconstruction: delayed remodeling and inferior mechanical 
function during long-term healing in sheep. Arthroscopy 24(4):448-458. 
Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, Rauterberg J, 
Lorkowski S. 2008. Production of type VI collagen by human macrophages: a 
new dimension in macrophage functional heterogeneity. J Immunol 
180(8):5707-5719. 
Sckell A, Leunig M, Fraitzl CR, Ganz R, Ballmer FT. 1999. The connective-tissue 
envelope in revascularisation of patellar tendon grafts. J Bone Joint Surg Br 
81(5):915-920. 
Scott A, Khan KM, Heer J, Cook JL, Lian O, Duronio V. 2005. High strain mechanical 
loading rapidly induces tendon apoptosis: an ex vivo rat tibialis anterior 
model. Br J Sports Med 39(5):e25. 
170 
 
Seida JC, LeBlanc C, Schouten JR, Mousavi SS, Hartling L, Vandermeer B, Tjosvold L, 
Sheps DM. 2010. Systematic review: nonoperative and operative treatments 
for rotator cuff tears. Ann Intern Med 153(4):246-255. 
Seiler JG, 3rd, Chu C, Abrahamsson SO, Gelberman RH. 1993a. The fate of 
autogenous tendon grafts. Iowa Orthop J 13:56-62. 
Seiler JG, 3rd, Chu CR, Amiel D, Woo SL, Gelberman RH. 1997. The Marshall R. Urist 
Young Investigator Award. Autogenous flexor tendon grafts. Biologic 
mechanisms for incorporation. Clin Orthop Relat Res(345):239-247. 
Seiler JG, 3rd, Gelberman RH, Williams CS, Woo SL, Dickersin GR, Sofranko R, Chu 
CR, Rosenberg AE. 1993b. Autogenous flexor-tendon grafts. A 
biomechanical and morphological study in dogs. J Bone Joint Surg Am 
75(7):1004-1014. 
Sharma P, Maffulli N. 2006. Biology of tendon injury: healing, modeling and 
remodeling. J Musculoskelet Neuronal Interact 6(2):181-190. 
Shin RH, Zhao C, Zobitz ME, Amadio PC, An KN. 2008. Mechanical properties of 
intrasynovial and extrasynovial tendon fascicles. Clin Biomech (Bristol, 
Avon) 23(2):236-241. 
Shino K, Horibe S. 1991. Experimental ligament reconstruction by allogeneic tendon 
graft in a canine model. Acta Orthop Belg 57 Suppl 2:44-53. 
Singer DI, Morrison WA, Gumley GJ, O'Brien BM, Mitchell GM, Barton RM, Frykman 
GK. 1989. Comparative study of vascularized and nonvascularized tendon 
grafts for reconstruction of flexor tendons in zone 2: an experimental study 
in primates. J Hand Surg Am 14(1):55-63. 
Sivakumar B, Akhavani MA, Winlove CP, Taylor PC, Paleolog EM, Kang N. 2008. 
Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J 
Hand Surg Am 33(1):49-58. 
Strickland JW. 1983. Management of acute flexor tendon injuries. Orthop Clin North 
Am 14(4):827-849. 
Sun M, Kingham PJ, Reid AJ, Armstrong SJ, Terenghi G, Downes S. 2010. In vitro and 
in vivo testing of novel ultrathin PCL and PCL/PLA blend films as peripheral 
nerve conduit. J Biomed Mater Res A 93(4):1470-1481. 
171 
 
Tachiiri H, Morihara T, Iwata Y, Yoshida A, Kajikawa Y, Kida Y, Matsuda K, Fujiwara 
H, Kurokawa M, Kawata M, Kubo T. 2010. Characteristics of donor and host 
cells in the early remodeling process after transplant of Achilles tendon with 
and without live cells for the treatment of rotator cuff defect--what is the 
ideal graft for the treatment of massive rotator cuff defects? J Shoulder 
Elbow Surg 19(6):891-898. 
Takahashi T, Kasashima Y, Ueno Y. 2004. Association between race history and risk 
of superficial digital flexor tendon injury in Thoroughbred racehorses. J Am 
Vet Med Assoc 225(1):90-93. 
Taras JS, Gray RM, Culp RW. 1994. Complications of flexor tendon injuries. Hand Clin 
10(1):93-109. 
Teli M, Chiodini F, Sottocasa R, Villa T. 2005. Influence of the diameters of tendon 
graft and bone tunnel in hamstring ACL reconstruction. A bovine model. Chir 
Organi Mov 90(3):281-285. 
Theobald P, Bydder G, Dent C, Nokes L, Pugh N, Benjamin M. 2006. The functional 
anatomy of Kager's fat pad in relation to retrocalcaneal problems and other 
hindfoot disorders. J Anat 208(1):91-97. 
Thorfinn J, Saber S, Angelidis IK, Ki SH, Zhang AY, Chong AK, Pham HM, Lee GK, 
Chang J. 2009. Flexor tendon tissue engineering: temporal distribution of 
donor tenocytes versus recipient cells. Plast Reconstr Surg 124(6):2019-2026. 
Towler DA, Gelberman RH. 2006. The alchemy of tendon repair: a primer for the 
(S)mad scientist. J Clin Invest 116(4):863-866. 
Victor J, Bellemans J, Witvrouw E, Govaers K, Fabry G. 1997. Graft selection in 
anterior cruciate ligament reconstruction--prospective analysis of patellar 
tendon autografts compared with allografts. Int Orthop 21(2):93-97. 
Vogel KG, Peters JA. 2005. Histochemistry defines a proteoglycan-rich layer in 
bovine flexor tendon subjected to bending. J Musculoskelet Neuronal 
Interact 5(1):64-69. 
Weiler A, Unterhauser FN, Bail HJ, Huning M, Haas NP. 2002. Alpha-smooth muscle 
actin is expressed by fibroblastic cells of the ovine anterior cruciate ligament 
and its free tendon graft during remodeling. J Orthop Res 20(2):310-317. 
172 
 
Williams IF, McCullagh KG, Silver IA. 1984. The distribution of types I and III collagen 
and fibronectin in the healing equine tendon. Connect Tissue Res 12(3-4):211-
227. 
Wong J, Bennett W, Ferguson MW, McGrouther DA. 2006a. Microscopic and 
histological examination of the mouse hindpaw digit and flexor tendon 
arrangement with 3D reconstruction. J Anat 209(4):533-545. 
Wong JK, Alyouha S, Kadler KE, Ferguson MW, McGrouther DA. 2010. The cell 
biology of suturing tendons. Matrix Biol 29(6):525-536. 
Wong JK, Cerovac S, Ferguson MW, McGrouther DA. 2006b. The cellular effect of a 
single interrupted suture on tendon. J Hand Surg Br 31(4):358-367. 
Wong JK, Lui YH, Kapacee Z, Kadler KE, Ferguson MW, McGrouther DA. 2009. The 
cellular biology of flexor tendon adhesion formation: an old problem in a 
new paradigm. Am J Pathol 175(5):1938-1951. 
Wu JL, Yeh TT, Shen HC, Cheng CK, Lee CH. 2009. Mechanical comparison of 
biodegradable femoral fixation devices for hamstring tendon graft--a 
biomechanical study in a porcine model. Clin Biomech (Bristol, Avon) 
24(5):435-440. 
Wu YF, Chen CH, Cao Y, Avanessian B, Wang XT, Tang JB. 2010. Molecular events of 
cellular apoptosis and proliferation in the early tendon healing period. J 
Hand Surg Am 35(1):2-10. 
Yasuda K, Tomita F, Yamazaki S, Minami A, Tohyama H. 2004. The effect of growth 
factors on biomechanical properties of the bone-patellar tendon-bone graft 
after anterior cruciate ligament reconstruction: a canine model study. Am J 
Sports Med 32(4):870-880. 
Zantop T, Gilbert TW, Yoder MC, Badylak SF. 2006. Extracellular matrix scaffolds are 
repopulated by bone marrow-derived cells in a mouse model of achilles 
tendon reconstruction. J Orthop Res 24(6):1299-1309. 
Zavahir F, McGrouther DA, Misra A, Smith K, Brown RA, Mudera V. 2001. A study of 
the cellular response to orientated fibronectin material in healing extensor 
rat tendon. J Mater Sci Mater Med 12(10-12):1005-1011. 
173 
 
Zavazava N, Kabelitz D. 2000. Alloreactivity and apoptosis in graft rejection and 
transplantation tolerance. J Leukoc Biol 68(2):167-174. 
Zhang ZZ, Zhong SZ, Sun B, Ho GT. 1990. Blood supply of the flexor digital tendon in 
the hand and its clinical significance. Surg Radiol Anat 12(2):113-117. 
 
 
 
 
 
 
 
 
174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
175 
 
Zinc Fixation 
 
Preparation of Zinc fixative (Beckstead J.H., 1994) 
   
For 500ml of zinc fixative solution 1.322g of Tris HCl and 0.194g of Tris base was added 
to 500mls of distilled water (100mM Tris.Hcl pH 7.4) and stirred continuously until the 
salts had dissolved. Following dissolution, under continuous stirring, 0.25 g of Calcium 
acetate (0.05% Calcium acetate) is added to the solution, followed by 2.5g of Zinc 
acetate (0.5% Zinc acetate)  then followed by 2.5g of Zinc Chloride (0.5% Zinc chloride). 
Once all the salt had dissolved the fixative is stored at 4°C until use. The final pH should 
be 6.5-7.5 
 
For mice who underwent suture wounding and proximal suture immobilization mice  
samples were placed into zinc fixative and stored at 4°C for 48 hours then transferred 
to 50% IMS solution prior to tissue processing. 
 
Decalcification 
Preparation of EDTA decalcification solution 
 
For 2 litres of 20% EDTA solution add to 1000 ml of 40% EDTA liquid to 850 mls of dH20 in 
a fume cupboard and stir continuously. Add slowly approx 150-160 mls of concentrated 
HCL under pH guidance to adjust pH to 7-7.4. This procedure should be performed with 
protective eye wear in a fume cupboard. 
 
The method of EDTA decalcification was used to demineralise the bone so that paraffin 
processing and whole digit sectioning could be performed. This solution was used to 
decalcify individual digits for a total of 15 days with solution changes every 5 days. 
Radiographs of the samples were performed on the 15th day to ensure complete 
decalcification using a dental x-ray machine (Faxitron, UK.) with power settings at 
45kVp and 5 second exposure. 
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Tissue Processor Program-Paraffin wax processing 
 
Following fixation samples were placed into an automated tissue processor (Tissue Tek 
Vacuum Infiltration Processor) following a program intended for skin samples which 
best preserved tendon architecture. This protocol was selected from a number of 
programs tested which gave the least brittleness in the tendon on sectioning. The 
pressure/vacuum cycles (p/v cycles) are fixed throughout processing. The wax 
impregnated tissue was then embedded in paraffin wax blocks.  
 
Process Solution  Time  
(Hr: Min) 
Temperature 
(°C) 
P/V cycle 
(On/Off) 
 
 
 
50% IMS 0:45 - On 
 70% IMS 0:45 - On 
 90% IMS 1:00 - On 
 100% IMS 0:30 - On 
 100%IMS 0:30 - On 
 100%IMS 1:00 - On 
 50:50 
IMS/Toluene 
0:30 - On 
 100% 
Toluene 
0:30 - On 
 100% 
Toluene 
0:30 - On 
 100% 
Toluene 
1:00 50 On 
 1
st
 wax 0:30 60 On 
 2
nd
 wax 0:30 60 On 
 3
rd
 wax 0:30 60 On 
 4
th
 wax 1:00 60 On 
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Buffers 
 
PBS(0.1M) 
 1 L PBS concentrate (1M Sigma Aldrich) 
60gm NaCl 
10L ddH2O 
 
PBS-Tween 
1 L PBS concentrate (1M Sigma Aldrich) 
60gm NaCl 
10L ddH2O 
10ml Tween 
 
Tris buffer 
 
12.1 gm TRIS Base 
1M HCl 
900ml dH2O 
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General staining 
 
Harris’ Haematoxylin Solution 
 
To make approximately 500mls of haematoxylin dissolve 4 g haematoxylin 
monohydrate in 40ml IMS. Place 760 mls of distilled water into a one litre heat proof 
flask and heat until approximately 60°C then add 80 g of aluminium potassium sulfate 
dodecahydrate (Sigma). Heat to 70°C and add alcohol solution. Heat to 75°C and add 
0.8g sodium iodate which should result in solution looking like port. Remove from heat 
and place into an ice/water bath and cool for 30 minutes. Add 32 ml of glacial acetic acid 
and stir at room temperature overnight. Filter dissolved solution through Whatman 
paper, bottle and store.  
   
1% Eosin Y 
 
To make 500 ml of Eosin Y add 5 g of eosin Y to 500ml of distilled water and stir until 
dissolved. Bottle and store. 
 
Nuclear fast red 
 
To make 500mls of nuclear fast red solution dissolve 25 g of aluminium sufate in 500mls 
of dH20. Then add 0.5 g of nuclear fast red and dissolve over a hot plate at 40°C. Filter 
and add a crystal of thymol. Bottle and store 
 
Miller’s Stain 
 
Brought from BDH 
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Alcian Blue pH 2.5 
 
3% Glacial Acetic Acid 
Acetic Acid- 3ml 
Distilled water 100 ml 
 
Alcian Blue solution 
 
3% Glacial Acetic Acid 100 ml 
Alcian Blue 8Gx 1gm 
Mix and adjust pH to 2.5 using acetic acid. Filter, add a thymol crystal and store at room 
temperature 
 
Picric Acid (1%) 
 
 5 ml Picric Acid 
500 ml 70% IMS 
 
The Picric Acid (Hopkins and Williams Ltd, Essex, UK) was dissolved in the  70% IMS in 
the fume hood and stored at room temperature. 
 
Biebrich Scarlet 
 
0.5 gm biebrich scarlet 
5 gm glacial acetic acid 
495 ddH2O 
 
The glacial acetic acid was mixed with the ddH2O to make 1% acetic acid solution. The 
biebrich scarlet (Gurr, BDH Laboratory  supplies) was then added and dissolved  with 
stirring. The stain was stored at room temperature. 
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PMA/PTA (50%/50%) 
 
12.5 gm phosphomolybdic acid 
12.5 gm phosphotungstic acid 
500 ml ddH2O 
 The phosphomolybdic acid (BDH laboratory supplies) and the phosphotungstic acid 
(BDH laboratory supplies) were separately dissolved in 250 ml of ddH2O. The two 
solutions were mixed thoroughly and stored at room temperature. 
 
Fast Green 
 
12,5 gm Fast Green 
12.5 ml glacial acetic acid 
487.5 ml ddH2O 
 
A 2.5 % Glacial acetic acid solution was prepared by combining the glacial acetic acid and 
the ddH2O. The Fast Green (Gurr, BDH laboratory supplies) was added and dissolved 
with stirring. The stain was stored at room temperature. 
 
0.5 % acidified Potassium Permanganate 
 
2.5 gm Potassium Permanganate 
15 ml sulphuric acid 
 485 ml dH2O 
 
Toluidine Blue Stock solution 
 
 1 gm Toluidine Blue 
100 ml 70% alcohol 
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Van Gieson Counter Stain 
 
50 ml saturated Picric acid solution 
9ml 1% aqueous acid fuchsin solution 
50 ml dH2O 
 
Postoperative Analgesia 
 
Subcutaneous Buprenorphine 0.05 mg/kg (Vetergesic-Reckitt Benckiser Healthcare UK 
Limited) 
0.25 ml of stock solution diluted in 4.75 ml of saline (In additive free vacutainer) 
Will stay active for two weeks  30 gm mice-0.2 ml for 0.1 mg/kg and 0.1 ml for 0.05 ml/kg 
 
Poly(ε-caprolactone) 3D electrospun bundles – in vivo study 
 
3D bundles were fabricated by electrospinning a 10 % w/v PCL (Mw 80,000) in acetone 
solution with parameters; voltage 20 kV, flow-rate 0.05 ml/min and distance to collector 
15 cm. A purpose-made mandrel of aluminium with diameter 120 mm and edge 
thickness of 3 mm (Fine Mandrel – FM) was mounted on a non-conductive Tufnol rod. 
Fibres were spun onto the edge of the mandrel rotating at a speed of 500 RPM for 15 
minutes, as this was sufficient time for complete coverage of the mandrel edge. The 
mat of fibres deposited on the mandrel edge was removed as a single long strip and cut 
every 3 cm along its length into smaller 
sheets. Each sheet of fibres was then submerged in distilled water and manually twisted 
to form a three-dimensional bundle that was left to dry on the open bench. 
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Sterilisation of electrospun samples 
 
To minimise the risk of infection all electrospun samples, including random and aligned 
2D fibrous mats, and 3D bundles and plaits were sterilised prior to use. Sterilisation 
through increasing concentrations of ethanol (VWR) was conducted in the class II 
microbiological safety cabinet (University of Manchester). Ethanol concentrations used 
included; 50, 70, 90 and 100 % v/v ethanol (diluted as necessary with distilled water). 
Samples were sterilised overnight for each concentration. Following sterilisation with 
100%ethanol, samples were washed twice in PBS. 
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Presentations and Posters from the Thesis 
 
Oral 
 
1) Oral presentation at British Association of Plastics Reconstructive and Aesthetic 
Surgeon summer meeting (BAPRAS) –July 2009 
 
2) Oral presentation at the European Hand Congress of June 2008 (FESSH/ EFHST) 
 
3) Oral presentation at University of Manchester Graduate Research Symposium July 
2009 
 
4) RCSENG Donor's annual meeting of the Shropshire Freemasons- February 2009 
 
5) University of Manchester Dermatological Sciences Winter meeting 2009 
 
Poster 
 
1) Royal college of Surgeons of England Research Evening, May 2009 
  
2) University of Manchester Faculty of Medicine Graduate Symposium, January 2009 
 
3) Poster Presentation at TERMIS (Tissue Engineering and Regenerative Medicine 
International Society September 2007) 
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Abbreviations 
 
ABC Avidin Biotin Complex 
Alpha- SMA Alpha smooth muscle actin 
BMT  Bone marrow transplant 
BrdU 5-Bromo-2-deoxyuridine 
C57/BLJ C57 black mice species 
CD  Cluster Differentiation  
CD 45 Pan leukocytic marker 
CD 3 Activated T cell marker 
ECM Extracellular matrix 
ECR Extensor Carpi Radialis 
Hsp47 Heat Shock Protein 47 
GDF Growth differentiation factor 
GFP Green fluorescent protein 
GFPBMT Green Fluorescent Protein Bone Marrow Transplant 
H&E Haematoxylin and eosin Y 
LacZ Beta galactosidase reporter gene 
MSC Mesenchymal Stem Cell 
PBS Phosphate buffered saline 
SEM Scanning Electron Microscope 
SIS-ECM Small Intestinal Submucosa-Extracellular matrix 
SLE Systemic Lupus Erythematosus 
TGFβ 1 Transforming growth factor  1 
TGFβ 3 Transforming growth factor 3 
TUNEL Terminal-deoxynucleotidyl Transferase Biotin dUTP End 
labelling 
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Glossary 
 
Syngeneic Genetically identical members of the same species 
Transgenic A transgenic animal is one that carries a foreign gene that has 
been deliberately inserted into its genome. 
Autograft Tissue transplanted from one part of the body to another in the 
same individual.  
Allograft Cell/Tissue/ Organ sourced from a genetically non-identical 
member of the same species 
Xenograft Transplantation of living cells, tissues or organs from one species 
to another 
Isograft A subset of allografts in which organs or tissues are transplanted 
from a donor to a genetically identical recipient (such as an 
identical twin) 
 
 
 
